PH26557A - Indolylpiperidine compounds - Google Patents
Indolylpiperidine compounds Download PDFInfo
- Publication number
- PH26557A PH26557A PH40436A PH40436A PH26557A PH 26557 A PH26557 A PH 26557A PH 40436 A PH40436 A PH 40436A PH 40436 A PH40436 A PH 40436A PH 26557 A PH26557 A PH 26557A
- Authority
- PH
- Philippines
- Prior art keywords
- phenyl
- piperidine
- indolyl
- hydroxy
- acid
- Prior art date
Links
- HNQZRUDJRPSFAU-UHFFFAOYSA-N 2-piperidin-1-yl-1h-indole Chemical class C1CCCCN1C1=CC2=CC=CC=C2N1 HNQZRUDJRPSFAU-UHFFFAOYSA-N 0.000 title description 9
- -1 3-indolyl Chemical group 0.000 claims description 189
- 150000001875 compounds Chemical class 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 58
- 239000002253 acid Substances 0.000 claims description 20
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 75
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 239000002585 base Substances 0.000 description 49
- 239000000203 mixture Substances 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 125000003545 alkoxy group Chemical group 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 27
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000000921 elemental analysis Methods 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 125000004423 acyloxy group Chemical group 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000003379 elimination reaction Methods 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 229960001866 silicon dioxide Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 9
- 238000006722 reduction reaction Methods 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- GOYMYMMZRLPMPO-ASVGJQBISA-N (2e,4e)-5-(4-hydroxy-3,5-dimethoxyphenyl)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide Chemical compound COC1=C(O)C(OC)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 GOYMYMMZRLPMPO-ASVGJQBISA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- RPAKPIHLJIEODQ-VDESZNBCSA-N (2e,4e)-5-(4-hydroxy-3-methoxyphenyl)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide Chemical compound C1=C(O)C(OC)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 RPAKPIHLJIEODQ-VDESZNBCSA-N 0.000 description 4
- DSKKWRMQFREVAD-UHFFFAOYSA-N 3-piperidin-1-yl-1h-indole Chemical compound C1CCCCN1C1=CNC2=CC=CC=C12 DSKKWRMQFREVAD-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- YXNKWHZCUWBSEN-UHFFFAOYSA-N 2-[4-(1h-indol-3-yl)piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1C1=CNC2=CC=CC=C12 YXNKWHZCUWBSEN-UHFFFAOYSA-N 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- QPQGTZMAQRXCJW-UHFFFAOYSA-N [chloro(phenyl)phosphoryl]benzene Chemical compound C=1C=CC=CC=1P(=O)(Cl)C1=CC=CC=C1 QPQGTZMAQRXCJW-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000010531 catalytic reduction reaction Methods 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 229960004319 trichloroacetic acid Drugs 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- ZWUFEOKUAIWQNG-PIHCAMFYSA-N (2e,4e)-5-[4-hydroxy-3,5-di(propan-2-yl)phenyl]-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide Chemical compound CC(C)C1=C(O)C(C(C)C)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 ZWUFEOKUAIWQNG-PIHCAMFYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- VIGMLAAKWQNCMP-UHFFFAOYSA-N 2-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 VIGMLAAKWQNCMP-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical compound C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- UYGBSRJODQHNLQ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzaldehyde Chemical compound CC1=CC(C=O)=CC(C)=C1O UYGBSRJODQHNLQ-UHFFFAOYSA-N 0.000 description 2
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052568 Urticaria chronic Diseases 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000024376 chronic urticaria Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 2
- UIKBOJQCBFQWBO-XMGZOKRTSA-N ethyl [4-[(1e,3e)-5-[4-[4-(1h-indol-3-yl)piperidin-1-yl]butylamino]-5-oxopenta-1,3-dienyl]-2,6-dimethoxyphenyl] carbonate Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1\C=C\C=C\C(=O)NCCCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 UIKBOJQCBFQWBO-XMGZOKRTSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 125000005023 xylyl group Chemical group 0.000 description 2
- RMXCTOJWDUCDBG-FCFGPSFYSA-N (2e,4e)-5-(2-hydroxy-3-methoxyphenyl)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide Chemical compound COC1=CC=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1O RMXCTOJWDUCDBG-FCFGPSFYSA-N 0.000 description 1
- HTKTXNNPGRFLBL-ASVGJQBISA-N (2e,4e)-5-(3,4-dimethoxyphenyl)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C=C\C(=O)NCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 HTKTXNNPGRFLBL-ASVGJQBISA-N 0.000 description 1
- XWSCODFQKADPHY-VPXADRJXSA-N (2e,4e)-5-(4-hydroxy-3,5-dimethoxyphenyl)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide;hydrochloride Chemical compound Cl.COC1=C(O)C(OC)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 XWSCODFQKADPHY-VPXADRJXSA-N 0.000 description 1
- ZFNUHPLDGRGPCX-LAKPREEESA-N (2e,4e)-5-(4-hydroxy-3,5-dimethoxyphenyl)-n-[3-[4-(1h-indol-3-yl)piperidin-1-yl]propyl]penta-2,4-dienamide Chemical compound COC1=C(O)C(OC)=CC(\C=C\C=C\C(=O)NCCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 ZFNUHPLDGRGPCX-LAKPREEESA-N 0.000 description 1
- QNZXAHIHUWGUCW-XCCLWPCOSA-N (2e,4e)-5-(4-hydroxy-3,5-dimethoxyphenyl)-n-[4-[4-(1h-indol-3-yl)piperidin-1-yl]butyl]penta-2,4-dienamide Chemical compound COC1=C(O)C(OC)=CC(\C=C\C=C\C(=O)NCCCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 QNZXAHIHUWGUCW-XCCLWPCOSA-N 0.000 description 1
- GOSUUJBBQTWXPJ-VNQMDCGWSA-N (2e,4e)-5-(4-hydroxy-3-methoxyphenyl)-n-[4-[4-(1h-indol-3-yl)piperidin-1-yl]butyl]penta-2,4-dienamide Chemical compound C1=C(O)C(OC)=CC(\C=C\C=C\C(=O)NCCCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 GOSUUJBBQTWXPJ-VNQMDCGWSA-N 0.000 description 1
- UIHVYTVOUXWFBI-VDESZNBCSA-N (2e,4e)-5-(4-hydroxy-3-methylphenyl)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]penta-2,4-dienamide Chemical compound C1=C(O)C(C)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 UIHVYTVOUXWFBI-VDESZNBCSA-N 0.000 description 1
- XEIJSCZBGIMJGR-GODDPXKCSA-N (2e,4e)-5-[3,5-dimethoxy-4-(2-methoxyethoxymethoxy)phenyl]-n-[4-[4-(1h-indol-3-yl)piperidin-1-yl]butyl]penta-2,4-dienamide Chemical compound C1=C(OC)C(OCOCCOC)=C(OC)C=C1\C=C\C=C\C(=O)NCCCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 XEIJSCZBGIMJGR-GODDPXKCSA-N 0.000 description 1
- IMVFSLPDWZSWLA-PLPQCDBPSA-N (2e,4e)-5-[3-methoxy-2-(2-methoxyethoxymethoxy)phenyl]penta-2,4-dienoic acid Chemical compound COCCOCOC1=C(OC)C=CC=C1\C=C\C=C\C(O)=O IMVFSLPDWZSWLA-PLPQCDBPSA-N 0.000 description 1
- XBQRYIOHRRHUGO-YDFGWWAZSA-N (2e,4e)-5-[4-(2-methoxyethoxymethoxy)-3,5-dimethylphenyl]penta-2,4-dienoic acid Chemical compound COCCOCOC1=C(C)C=C(\C=C\C=C\C(O)=O)C=C1C XBQRYIOHRRHUGO-YDFGWWAZSA-N 0.000 description 1
- VULORCIEWQOQKS-GGWOSOGESA-N (2e,4e)-5-[4-(2-methoxyethoxymethoxy)-3-methylphenyl]penta-2,4-dienoic acid Chemical compound COCCOCOC1=CC=C(\C=C\C=C\C(O)=O)C=C1C VULORCIEWQOQKS-GGWOSOGESA-N 0.000 description 1
- VUEKURPWEQMKMU-GGWOSOGESA-N (2e,4e)-5-[4-methoxy-3-(2-methoxyethoxymethoxy)phenyl]penta-2,4-dienoic acid Chemical compound COCCOCOC1=CC(\C=C\C=C\C(O)=O)=CC=C1OC VUEKURPWEQMKMU-GGWOSOGESA-N 0.000 description 1
- ALCPLYSPYYNRIQ-LMZONGNASA-N (2e,4e)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]-5-[4-(2-methoxyethoxymethoxy)-3,5-di(propan-2-yl)phenyl]penta-2,4-dienamide Chemical compound C1=C(C(C)C)C(OCOCCOC)=C(C(C)C)C=C1\C=C\C=C\C(=O)NCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 ALCPLYSPYYNRIQ-LMZONGNASA-N 0.000 description 1
- SHBRHLWQMMNPCD-RIALUSDFSA-N (2e,4e)-n-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]-5-[4-(2-methoxyethoxymethoxy)-3,5-dimethylphenyl]penta-2,4-dienamide Chemical compound C1=C(C)C(OCOCCOC)=C(C)C=C1\C=C\C=C\C(=O)NCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 SHBRHLWQMMNPCD-RIALUSDFSA-N 0.000 description 1
- QZSOXMDRRNPQJV-LAKPREEESA-N (2e,4e)-n-[3-[4-(1h-indol-3-yl)piperidin-1-yl]propyl]-5-[3-methoxy-4-(2-methoxyethoxymethoxy)phenyl]penta-2,4-dienamide Chemical compound C1=C(OC)C(OCOCCOC)=CC=C1\C=C\C=C\C(=O)NCCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 QZSOXMDRRNPQJV-LAKPREEESA-N 0.000 description 1
- VGRXAHXMIDCTNV-UHFFFAOYSA-N (6-chlorobenzotriazol-1-yl) 4-chlorobenzenesulfonate Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)ON1C2=CC(Cl)=CC=C2N=N1 VGRXAHXMIDCTNV-UHFFFAOYSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- DOYQIFNDQMFQSA-GQCTYLIASA-N (e)-3-[3-methoxy-4-(2-methoxyethoxymethoxy)phenyl]prop-2-enoic acid Chemical compound COCCOCOC1=CC=C(\C=C\C(O)=O)C=C1OC DOYQIFNDQMFQSA-GQCTYLIASA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- MASDFXZJIDNRTR-UHFFFAOYSA-N 1,3-bis(trimethylsilyl)urea Chemical compound C[Si](C)(C)NC(=O)N[Si](C)(C)C MASDFXZJIDNRTR-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- CHZXTOCAICMPQR-UHFFFAOYSA-N 2-(2-bromoethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCBr)C(=O)C2=C1 CHZXTOCAICMPQR-UHFFFAOYSA-N 0.000 description 1
- DJQTXIYJHCNPSL-UHFFFAOYSA-N 2-(2-methoxyethoxymethoxy)benzaldehyde Chemical compound COCCOCOC1=CC=CC=C1C=O DJQTXIYJHCNPSL-UHFFFAOYSA-N 0.000 description 1
- VKJCJJYNVIYVQR-UHFFFAOYSA-N 2-(3-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCBr)C(=O)C2=C1 VKJCJJYNVIYVQR-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- UZPJXXDTHSFGPR-UHFFFAOYSA-N 2-[3-[4-(1h-indol-3-yl)piperidin-1-yl]propyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 UZPJXXDTHSFGPR-UHFFFAOYSA-N 0.000 description 1
- ZQKOGGITTXFXDU-UHFFFAOYSA-N 2-[4-[4-(1h-indol-3-yl)piperidin-1-yl]butyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 ZQKOGGITTXFXDU-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- OCMQWPUBOZJTLP-UHFFFAOYSA-N 3,5-dichloro-4-(2-methoxyethoxymethoxy)benzaldehyde Chemical compound COCCOCOC1=C(Cl)C=C(C=O)C=C1Cl OCMQWPUBOZJTLP-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- DFRLERNBAUTIOZ-UHFFFAOYSA-N 3,5-ditert-butyl-4-(2-methoxyethoxymethoxy)benzaldehyde Chemical compound COCCOCOC1=C(C(C)(C)C)C=C(C=O)C=C1C(C)(C)C DFRLERNBAUTIOZ-UHFFFAOYSA-N 0.000 description 1
- XTSWIXOWDXKQBT-UHFFFAOYSA-N 3-[4-(1h-indol-3-yl)piperidin-1-yl]propan-1-amine Chemical compound C1CN(CCCN)CCC1C1=CNC2=CC=CC=C12 XTSWIXOWDXKQBT-UHFFFAOYSA-N 0.000 description 1
- MPSPDUBVKSZXLF-UHFFFAOYSA-N 4-(2-methoxyethoxymethoxy)-3,5-dimethylbenzaldehyde Chemical compound COCCOCOC1=C(C)C=C(C=O)C=C1C MPSPDUBVKSZXLF-UHFFFAOYSA-N 0.000 description 1
- NTFBLWDLEPWZEH-UHFFFAOYSA-N 4-(2-methoxyethoxymethoxy)-3-methylbenzaldehyde Chemical compound COCCOCOC1=CC=C(C=O)C=C1C NTFBLWDLEPWZEH-UHFFFAOYSA-N 0.000 description 1
- IGIJSFNBEUBMGB-UHFFFAOYSA-N 4-(cyclohexyliminomethylideneamino)-n,n-diethylcyclohexan-1-amine Chemical compound C1CC(N(CC)CC)CCC1N=C=NC1CCCCC1 IGIJSFNBEUBMGB-UHFFFAOYSA-N 0.000 description 1
- JLQULPQWPLYQSS-UHFFFAOYSA-N 4-[4-(1h-indol-3-yl)piperidin-1-yl]butan-1-amine Chemical compound C1CN(CCCCN)CCC1C1=CNC2=CC=CC=C12 JLQULPQWPLYQSS-UHFFFAOYSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YOFZCLRRRXBCME-PIHCAMFYSA-N [2-ethoxycarbonyloxy-4-[(1e,3e)-5-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethylamino]-5-oxopenta-1,3-dienyl]phenyl] ethyl carbonate Chemical compound C1=C(OC(=O)OCC)C(OC(=O)OCC)=CC=C1\C=C\C=C\C(=O)NCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 YOFZCLRRRXBCME-PIHCAMFYSA-N 0.000 description 1
- KMRFTKHVDLAEEW-RIALUSDFSA-N [4-[(1e,3e)-5-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethylamino]-5-oxopenta-1,3-dienyl]-2,6-dimethoxyphenyl] acetate Chemical compound COC1=C(OC(C)=O)C(OC)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 KMRFTKHVDLAEEW-RIALUSDFSA-N 0.000 description 1
- XTENRICKNGIPEB-ASVGJQBISA-N [4-[(1e,3e)-5-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] acetate Chemical compound C1=C(OC(C)=O)C(OC)=CC(\C=C\C=C\C(=O)NCCN2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 XTENRICKNGIPEB-ASVGJQBISA-N 0.000 description 1
- LYBZFIUEFPLKHW-RIALUSDFSA-N [4-[(1e,3e)-5-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] propanoate Chemical compound C1=C(OC)C(OC(=O)CC)=CC=C1\C=C\C=C\C(=O)NCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 LYBZFIUEFPLKHW-RIALUSDFSA-N 0.000 description 1
- LVNGLDSNRYEGSR-HCCCJCESSA-N [4-[(1e,3e)-5-[4-[4-(1h-indol-3-yl)piperidin-1-yl]butylamino]-5-oxopenta-1,3-dienyl]-2,6-dimethoxyphenyl] propanoate;hydrochloride Chemical compound Cl.C1=C(OC)C(OC(=O)CC)=C(OC)C=C1\C=C\C=C\C(=O)NCCCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 LVNGLDSNRYEGSR-HCCCJCESSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- WYYQVWLEPYFFLP-UHFFFAOYSA-K chromium(3+);triacetate Chemical compound [Cr+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WYYQVWLEPYFFLP-UHFFFAOYSA-K 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- KJXYSJQEAKWUCZ-YDFGWWAZSA-N ethyl (2e,4e)-5-[3,5-dichloro-4-(2-methoxyethoxymethoxy)phenyl]penta-2,4-dienoate Chemical compound CCOC(=O)\C=C\C=C\C1=CC(Cl)=C(OCOCCOC)C(Cl)=C1 KJXYSJQEAKWUCZ-YDFGWWAZSA-N 0.000 description 1
- WCAFCCGSNVLMJV-XSIURBDDSA-N ethyl (2e,4e)-5-[3-methoxy-2-(2-methoxyethoxymethoxy)phenyl]penta-2,4-dienoate Chemical compound CCOC(=O)\C=C\C=C\C1=CC=CC(OC)=C1OCOCCOC WCAFCCGSNVLMJV-XSIURBDDSA-N 0.000 description 1
- MIHUTPSXHLWIBL-KQQUZDAGSA-N ethyl (2e,4e)-5-[4-(2-methoxyethoxymethoxy)-3-methylphenyl]penta-2,4-dienoate Chemical compound CCOC(=O)\C=C\C=C\C1=CC=C(OCOCCOC)C(C)=C1 MIHUTPSXHLWIBL-KQQUZDAGSA-N 0.000 description 1
- LXLODBXSCRTXFG-BQYQJAHWSA-N ethyl (e)-4-diethoxyphosphorylbut-2-enoate Chemical compound CCOC(=O)\C=C\CP(=O)(OCC)OCC LXLODBXSCRTXFG-BQYQJAHWSA-N 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- VOXCUZFWWKTYKT-PIHCAMFYSA-N ethyl [4-[(1e,3e)-5-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethylamino]-5-oxopenta-1,3-dienyl]-2,6-dimethoxyphenyl] carbonate Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1\C=C\C=C\C(=O)NCCN1CCC(C=2C3=CC=CC=C3NC=2)CC1 VOXCUZFWWKTYKT-PIHCAMFYSA-N 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-O hydron;1,2-oxazole Chemical compound C=1C=[NH+]OC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-O 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical compound CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- JVHPKYBRJQNPAT-UHFFFAOYSA-N n-cyclohexyl-2,2-diphenylethenimine Chemical compound C1CCCCC1N=C=C(C=1C=CC=CC=1)C1=CC=CC=C1 JVHPKYBRJQNPAT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000000552 p-cresyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1O*)C([H])([H])[H] 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- SDVVLIIVFBKBMG-UHFFFAOYSA-N penta-2,4-dienoic acid Chemical compound OC(=O)C=CC=C SDVVLIIVFBKBMG-UHFFFAOYSA-N 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000004360 trifluorophenyl group Chemical group 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
i == al nL . Ly _ 1 - 26557 - CL you zl
NEW INDOLYLPIPERIDINE COMPOUNDS, PROCESSES
FOR THE PREPARATION THEREOF AND PHARMA-
CEUTICAL COMPOSITION COMPRISING THE SAME
This application is a continuation-in-part of Philippine
Application Serial No. 38024 . filed on January 10, 1989. .
This invention relates to new indolylpiperidine compounds and pharmaceutically acceptable salts thereof.
More particularly, it relates to new indolylpiperidine compounds and pharmaceutically acceptable salts thereof which have antiallergic activity and/or anti-SRS-A activity,
CC to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a ’ 15 method for the treatment of allergic disease, inflammation etc. in human being or animals.
One object of this invention is to provide new indolylpiperidine compounds and pharmaceutically acceptable salts thereof which possess antiallergic activity and/or anti-SRS-A activity.
Another object of this invention is to provide processes for the preparation of said indolylpiperidine compounds or salts thereof.
A further object of this invention is to provide a w , - 2 - pharmaceutical composition comprising, as an active ingredient, said indolylpiperidine compounds or pharmaceutically acceptable salts thereof.
Still further object of this invention is to provide a therapeutical method for the treatment of allergic disease, inflammation or the like, for example, allergic asthma, allergic rhinitis, allergic conjunctivitis,: , allergic dermatitis [e.g. chronic urticaria, etc:], psoriasis, hepatitis, pahcreatitis, arthritis, nephritis, inflammatory bowel disease, septic shock, arteriosclerosis, r myocardial infarction, cerebral vasospasm : or the like, in hjinan being or animals.
Some indolylpiperidine compounds having anti- allergic activity have been known as described in
British Patent Application Publication No. 2093455.
Some amide derivatives having anti-allergic activity have been known as described in European
Patent Application Publication No. 157420.
The object indolylpiperidine compounds of this invention are new and can be represented by the following general formula [I] : 2 { N-A-NHCO-B-R'
A HH
H wherein rt is aryl substituted with substituent (s) selected from the group consisting of hydroxy, protected hydroxy, halogen and lower alkoxy,
A is lower alkylene, and }
B is lower alkenylene.
The object compound [I] or its salt can be prepared by processes as illustrated in the following reaction schemes.
- _ 3 =
Process 1
RY -B-COOH [I11] or its reactive derivative at the carboxy group or 1
N-A-NH, a salt thereof N-A-NHCO-B-R - = ¢
N N
H H
[II] (I] or its reactive derivative or its salt : at the amino group or a salt thereof
Process 2
Elimination of the hydroxy- protective . group - : . 1
N-A-NHCO-B-R= ——m———— 1
N-A-NHCO-B- 2 CIT C) 2 Te BR
N N
H H
[1a] [Ib] or its salt or its salt
Process 3
Acylation - 1 1-A-NHCO-B-R;, _— Og ] re - ~~ N
H H
[Ib] (Ic] or its salt or its salt
. C4 wherein R is aryl substituted with protected hydroxy, with protected hydroxy and halogen, or with protected hydroxy and lower alkoxy,
RS is aryl substituted with hydroxy, with hydroxy and halogen, or with hydroxy and lower alkoxy, rR is aryl substituted with acyloxy, with acyloxy and halogen, or with acyloxy and lower : alkoxy, and rl, A and B are each as defined above.
In the above and subsequent descriptions of the present specification, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following.
The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided.
Suitable "aryl" may be phenyl, naphthyl, phenyl substituted with lower alkyl [e.g. tolyl, mesityl, cumenyl, xylyl, diethylphenyl, diisopropylphenyl, di-tert-butyl- phenyl, etc.] or the like. ; Suitable "protected hydroxy" may be substituted lower alkoxy such as lower alkoxy (lower)alkoxy (lower)- alkoxy [e.g. methoxyethoxymethoxy, etc.], substituted or unsubstituted ar (lower)alkoxy (e.g. benzyloxy, nitrobenzyloxy, etc.], acyloxy such as lower alkanoyloxy [e.g. formyloxy, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy, hexanoyloxy, 3,3-dimethylbutyryloxy, etc.], lower alkoxy- carbonyloxy [e.g. methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, isopropoxycarbonyloxy, butoxycarbonyl- oxy, isobutoxycarbonyloxy, tert-butoxycarbonyloxy, pentyloxycarbonyloxy, hexyloxycarbonyloxy, etc.], sulfonyloxy [e.g. mesyloxy, tosyloxy, benzenesulfonyloxy, » etc.], substituted or unsubstituted ar (lower)alkoxy- carbonyloxy (e.g. benzyloxycarbonyloxy, bromobenzyloxy- carbonyloxy, etc.] etc.,
oe Ce tri (lower)alkylsilyloxy (e.g. trimethylsilyloxy, etc.] or the like.
Suitable "halogen" is fluorine, chlorine, bromine and iodine.
Suitable "acyloxy" may be the same as above-mentioned acyloxy enumerated for protected hydroxy.
Suitable "lower alkoxy" may be a straight or branched one such as methoxy, ethoxy, Propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy or the like, in which the preferable one is
C1-Cy alkoxy and the most preferable one is methoxy.
Preferable examples of "aryl substituted with sub- stituent(s) selected from the group consisting of hydroxy, protected hydroxy, halogen and lower alkoxy" may be mono-, or di-, or trihydroxyphenyl; mono-, Or di-, or tri (halo)phenyl [e.g. chlorophenyl, fluorophenyl, dichlorophenyl, trifluorophenyl, etc.]; mono-, or di-, or tri (lower) alkylphenyl [e.g. tolyl, mesityl, cumenyl, xylyl, ethylphenyl, diethylphenyl, isopropylphenyl, diisopropylphenyl, di-tert-butylphenyl, etc.]; mono-, or di-, or tri (lower)alkoxyphenyl [e.g. methoxy- phenyl, ethoxyphenyl, dimethoxyphenyl, trimethoxyphenyl, diethoxyphenyl, diisopropoxyphenyl, etc.]; mono-, Or dihydroxy and mono-, Or di (lower)alkoxy substituted phenyl [e.q. methoxy (hydroxy) phenyl, ethoxy (hydroxy) - phenyl, isopropoxy (hydroxy) phenyl, dimethoxy (hydroxy) - phenyl, diethoxy (hydroxy) phenyl, diisopropoxy (hydroxy) = phenyl, methoxy (dihydroxy) phenyl, methoxy (ethoxy) - hydroxyphenyl, etc.]; mono-, or dihydroxy and mono—, Or di (lower) alkyl substituted phenyl (e.g. methyl (hydroxy) - phenyl, ethyl (hydroxy) phenyl, propyl (hydroxy) phenyl, isopropyl (hydroxy) phenyl, dimethyl (hydroxy) phenyl, diethyl (hydroxy) phenyl, diisopropyl (hydroxy)phenyl, di-tert-butyl (hydroxy) phenyl, methyl (dihydroxy) phenyl, methyl (ethyl) hydroxyphenyl, etc.]; mono-, or dihydroxy and mono-, or dihalo substituted phenyl [e.g. chloro- (hydroxy) phenyl, dichloro (hydroxy)phenyl, fluoro- (hydroxy) phenyl, chloro (dihydroxy)phenyl, etc.l; mono-, or di-, or tri-protected hydroxy substituted phenyl such as mono-, or di-, or trif{lower alkoxy (lower) - alkoxy (lower) alkoxylphenyl {[e.g. mono-, or di-, or tri (methoxyethoxymethoxy)phenyl, etc.], mono-, or di-, or triacyloxyphenyl [e.g. mono-, or di-, or tri (lower) - alkanoyloxyphenyl (e.g. formyloxyphenyl, acetyloxyphenyl, propionyloxyphenyl, diacetyloxyphenyl, dipropionyloxy- phenyl, triacetyloxyphenyl, etc.), mono-, or di-, or tri (lower)alkoxycarbonyloxyphenyl (e.g. methoxycarbonyl- oxyphenyl, ethoxycarbonyloxyphenyl, diethoxycarbonyloxy- phenyl, triethoxycarbonyloxyphenyl, etc.) , etc.] or the like; mono-, or di (lower)alkoxy and mono-, OX di- protected hydroxy substituted phenyl such as mono-, Or di (lower)alkoxy and mono-, or di[lower alkoxy (lower) = alkoxy (lower) alkoxylsubstituted phenyl [e.g. methoxy- (methoxyethoxymethoxy) phenyl, ethoxy (methoxyethoxy- methoxy) phenyl, dime thoxy (methoxyethoxymethoxy) phenyl, : diethoxy (me thoxyethoxymethoxy)phenyl, diisopropoxy- (methoxyethoxymethoxy) phenyl, etc.], mono-, or diacyloxy and mono-, Or di (lower) alkoxy substituted phenyl (e.g. mono-, or di (lower) alkanoyloxy and mono-, or di (lower)alkoxy substituted phenyl (e.g. acetyloxy- (methoxy) phenyl, propionyloxy (methoxy) phenyl, acetyloxy- (ethoxy) phenyl, acetyloxy (dimethoxy) phenyl, propionyloxy- (dimethoxy) phenyl, acetyloxy (diethoxy) phenyl, acetyloxy- (diisopropoxy) phenyl, diacetyloxy (methoxy)phenyl, etc.), mono-, or di (lower)alkoxycarbonyloxy and mono-, OI di (lower)alkoxy substituted phenyl (e.g. methoxycarbonyl- oxy (methoxy) phenyl, ethoxycarbonyloxy (methoxy) phenyl, ethoxycarbonyloxy (ethoxy) phenyl, methoxycarbonyloxy- (dimethoxy) phenyl, ethoxycarbonyloxy (dimethoxy) phenyl, ethoxycarbonyloxy (diethoxy) phenyl, ethoxycarbonyloxy- (diisopropoxy)phenyl, etc.), etc.] or the like;
. Ca mono-, or di(lower)alkyl and mono-, Or di- protected hydroxy substituted phenyl such as mono-, Or di (lower)alkyl and mono—-, Or di [lower alkoxy (lower)- alkoxy (lower)alkoxy] substituted phenyl (e.g. methyl-
(methoxyethoxymethoxy) phenyl, ethyl (methoxyethoxymethoxy)- phenyl, dimethyl (methoxyethoxymethoxy) phenyl, diethyl- (methoxyethoxymethoxy) phenyl, diisopropyl (methoxyethoxy- me thoxy) phenyl, di-tert-butyl (methoxyethoxymethoxy)phenyl, etc.], mono-, or diacyloxy and mono-, Or di (lower)alkyl
‘substituted phenyl [e.g. mono-, or di (lower) alkanoyloxy and mono-, or di (lower)alkyl substituted phenyl (e.g. acetyloxy (methyl) phenyl, propionyloxy (methyl)phenyl, ’ acetyloxy (ethyl) phenyl, acetyloxy (dimethyl) phenyl, propionyloxy (dimethyl) phenyl, acetyloxy (diethyl) phenyl,
acetyloxy (diisopropyl) phenyl, diacetyloxy (methyl) phenyl, etc.), mono-, or di(lower)alkoxycarbonyloxy and mono-,
: or di (lower)alkyl substituted phenyl (e.g. methoxycarbonyl- SL oxy (methyl) phenyl, ethoxycarbonyloxy (methyl) phenyl, ethoxycarbonyloxy (ethyl) phenyl. methoxycarbonyloxy-
(dimethyl) phenyl, ethoxycarbonyloxy (dimethyl) phenyl, ethoxycarbonyloxy (diethyl) phenyl, ethoxycarbonyloxy- (diisopropyl) phenyl, etc.), etc.] or the like; and mono-, or dihalo and mono-, Or di- protected hydroxy substituted phenyl such as mono-, Or dihalo and mono-,
or di [lower alkoxy (lower) alkoxy (lower) alkoxy]- substituted phenyl [e.g. chloro (methoxyethoxymethoxy)- phenyl, dichloro (methoxyethoxymethoxy) phenyl, fluoro- :
(methoxyethoxymethoxy) phenyl, etc.], mono-, or diacyloxy and mono-, Or dihalo substituted phenyl (e.g. mono-, OI di (lower) alkanoyloxy and mono—, OF dihalo substituted phenyl (e.g. acetyloxy (chloro)phenyl, propionyloxy-
(chloro) phenyl, acetyloxy (dichloro) phenyl, etc.), mono-, or di (lower)alkoxycarbonyloxy and mono-, or dihalo substituted phenyl (e.g. me thoxycarbonyloxy (chloro)phenyl,
ethoxycarbonyloxy (chloro) phenyl, ethoxycarbonyloxy-
(dichloro) phenyl, etc.), etc.], or the like.
. : Ca
Preferable examples of "aryl substituted with protected hydroxy, with protected hydroxy and halogen, © or with protected hydroxy and lower alkoxy" may be the same as above-mentioned mono-, or di-, or tri- protected hydroxy substituted phenyl; . mono-, or dihalo and mono-, or di- protected hydroxy ‘substituted phenyl; mono-, or di (lower)alkoxy and mono-, Or di- protected hydroxy substituted phenyl; and mono-, or di(lower)alkyl and mono-, or di- protected hydroxy substituted phenyl.
Preferable examples of "aryl substituted with hydroxy, with hydroxy and halogen, or with hydroxy and lower alkoxy" may be the same as above-mentioned mono-, or di-, or trihydroxy phenyl; mono-, or dihydroxy and mono-, or dihalo substituted phenyl; mono-, or dihydroxy and mono-, or di (lower)alkoxy substituted phenyl; and mono-, or dihydroxy and mono-, or di(lower)alkyl - substituted phenyl.
Preferable examples of "aryl substituted with acyloxy, with acyloxy and halogen, or with acyloxy and lower alkoxy" may be the same as above-mentioned mono-, or di-, or triacyloxyphenyl; nono-, or diacyloxy and mono-, or dihalo substituted phenyl; mono-, or diacyloxy and mono-, or di (lower)alkoxy substituted phenyl; and mono- or diacyloxy and mono- or di (lower)alkyl substituted phenyl.
Suitable "lower alkylene" may be a straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, ethylethylene, propylene, pentamethylene, hexamethylene or the like. | E
Suitable "lower alkenylene" may be vinylene,
\ Cg propenylene, butenylene, pentenylene, butadienylene, pentadienylene or the like.
Suitable pharmaceutically acceptable salts of the object compound [I] are conventional non-toxic salts and include a metal salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.] and an alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.], an acid addition salt such as an organic acid addition salt (e.g. formate, acetate, trifluoroacetate, citrate, fumarate, maleate, tartrate, methanesul fonate, succinate, benzenesulfonate, toluenesulfonate, etc.], an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], a salt with an amino acid fe.qg. aspartic acid salt, glutamic acid salt, etc. ] and the like. :
With respect to the salts of the compounds [Ia], [Ib] and [Ic] in the Processes 2 and 3,it is to be noted that these compounds are included within the scope of the compound [I], to be continued on the next page and accordingly the suitable examples of the salts of these compounds are to be referred to those as exemplified for the object compound (1).
The processes for preparing the object compounds (I) of the present invention are explained in detail in the following.
Process 1 :
The object compound [I] or its salt can be pre- pared by reacting a compound [II] or its reactive derivative at the amino group or a salt thereof with a compound [III] or its reactive derivative at the carboxy group or a salt thereof. : :
Suitable reactive derivative at the amino group of the compound [II] may include Schiff's base type imino or its tautomeric enamine type isomer formed by. the reaction of the compound [II] with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative ; formed by the reaction of the compound: [II] with a silyl compound such as bis (trimethylsilyl)acetamide, mono {(trimethylsilyl)acetamide, bis (trimethylsilyl) urea or the like; a derivative formed by reaction of the compound [II] with phosphorus trichloride or phosgene, and the like.
Suitable salts of the compound [II] and its reactive derivative can be referred to the acid addition salt as exemplified for the compound [1].
Suitable reactive derivative at the carboxy group of the compound [III] may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric
So -11- acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid (e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid (e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; or an activated ester (e.g. cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [ (cH) N=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thiodster, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethyl- hydroxylamine, 1-hydroxy-2- (1H) ~pyridone, N-hydroxy- succinimide, N-hydroxyphthalimide, 1-hydroxy-1H- benzotriazole, etc.], and the like. These reactive deri- vatives can optionally be selected from them according to the kind of the compound [III] to be used.
Suitable salts of the compound [III] and its reactive derivative may be a base salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.], an alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.], an ammonium salt, an organic base salt [e.q. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.], or the like.
The reaction is usually carried out in a conven- tional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with water.
In this reaction, when the compound (I1I] is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide;
N-cyclohexyl-N'-morpholinoethylcarbodiimide;
N-cyclohexyl-N'- (4-diethylaminocyclohexyl) carbodiimide;
N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide;
N-ethyl-N'- (3-dimethylaminopropyl) carbodiimide; N,N'- carbonylbis- (2-methylimidazole); pentamethyleneketene-
N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; l-alkoxy-l-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; : phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; diphenyl phosphorylazide; diphenylphosphinic chloride; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.); triphenylphosphine; : } 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m- " sulfophenyl)isoxazolium hydroxide intramolecular salt; 1- (p-chlorobenzenesulfonyloxy) -6-chloro-lH-benzotriazole; so-called Vilsmeier. reagent prepared by the reaction of
N,N-dimethyl formamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.
The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri (lower)alkylamine, pyridine,
’ | - 13 -
N- (lower) alkylmorpholine, N,N-di (lower) alkylbenzylamine, or the like.
The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
Process 2
The compound [Ib] or its salt can be prepared by subjecting a compound [Ia] or its salt to elimination reaction of the hydroxy-protective group.
This reaction is carried out in accordance with a : conventional method such as hydrolysis, reduction or the like.
The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid. :
Suitable base may include an inorganic base and : an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.qg. ’ magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine le.g. trimethylamine, triethylamine, etc.]; picoline 1,5-diazabicyclo{4.3.0]non-5-ene, 1,4-diazabicyclo- [2.2.2)octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, Or the like.
Suitable acid may include an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloro- acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, etc.].
The elimination using Lewis acid such as trihalo- acetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].
The reaction is usually carried out in a solvent oN - 14 - such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, tetrachloromethane, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction.
A liquid base or acid can be also used as the solvent.
The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction.
Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.) or metallic compound [e.g. chromium chloride, : chromium acetate, etc.] and an organic or inorganic acid ' 15 (e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].
Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, . colloidal platinum, platinum oxide, platinum wire, etc.}, palladium catalysts (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts e.g. reduced nickel, nickel oxide, Raney nickel, .etc.]}, cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.}, iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper,
Ullman copper, etc.] and the like.
The reduction is usually carried out in a conven- ‘tional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol,
N,N-dimethyl formamide, or a mixture thereof.
Additionally, in case that the above-mentioned acids to '
v ' - 15 -~ be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above- mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.
The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to heating.
Process 3
The object compound [Ic] or its salt can be prepared by reacting a compound [Ib] or its salt with an acylating agent.
Suitable acylating agents are the corresponding carboxylic acid or sulfonic acid compounds, which are represented by the formula : R% OH wherein R? is acyl, and reactive derivatives thereof. :
Suitable "acyl" may be the same as acyl group for "acyloxy" as exemplified above. : Suitable said reactive derivatives can be referred } to the ones at the carboxy groups of the compound [III] as exemplified above. The kind of such reactive derivatives can be selected depending on the kind of acyl group to be introduced.
The reaction is usually carried out in a conven- tional solvent, such as methylene chloride, chloroform, benzene, toluene, pyridine, diethyl ether, dioxane, tetrahydrofuran, acetone, acetonitrile, ethyl acetate,
N,N-dimethylformamide or any other organic solvent which does not adversely affect the reaction. In case that the acylating agent is liquid, it can also be used as a solvent.
In case that the carboxylic acid compounds are used as . acylating agent in the free acid form or salt form, it is preferable to carry out the reaction in the presence of a conventional condensing agent such as N,N'- dicyclohexylcarbodiimide or the like.
The reaction temperature is not critical and the reaction can be carried out under cooling, at ambient temperature, or under heating.
This reaction is preferably carried out in the presence of an inorganic base, for example an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, or an alkali metal carbonate or hydrogen carbonate such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, or in the presence of an organic base, for example a tertiary amine such as triethylamine, pyridine,
N-methylmorpholine or N,N-dimethylaniline.
Among the starting compounds [II] and [III], some of them are new and can be prepared by processes as illustrated in the following reaction schemes.
Process A rR3-a-x (V] or its salt
NH &——— N-A-R step 1
N N
H H
[IV] [VI] or its salt or its salt
Elimination of the amino-protective group -A-NH, ee J .
H
Step 2 [II] "or its salt
* \ - 17 -
Process B
Oo “2159 pci, 5’ -&" [VIII]
CH 07 a . 1 (Wittig reaction) 1 4
R™-CHO _— > R"-CH=CH-B'-R [VII] Step 1 [IX] or its salt or its salt
Elimination of the : carboxy-protective group
EE RY-CH=CH-B'-COOH
Step 2 [IIIa] or its salt wherein R3 is protected amino, 4 is protected carboxy, : B' is lower alkylene or lower alkenylene,
X is a leaving group, r! and A are each as defined above.
Suitable "protected amino" may be acylamino such as substitutad or unsubstituted lower alkanoylamino [e.g. formylamino, acetylamino, propionylamino, trifluoroacetyl- amino, etc.], phthaloylimino, lower alkoxycarbonylamino [e.g. tert-butoxycarbonylamino, tert-amyloxycarbonylamino, etc.], substituted or unsubstituted aralkyloxycarbonylamino [e.g. benzyloxycarbonylamino, p-nitrobenzyloxycarbonylamino, etc.], substituted or unsubstituted arenesulfonylamino [e.g. benzenesulfonylamino, tosylamino, etc.], nitrophenylsul fenylamino, or the like, aralkylamino [e.g. tritylamino, benzylamino, etc.] or the like.
Suitable "protected carboxy" may be carboxy group protected by conventional protective group such as lower alkoxycarbonyl [e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, botoxycarbonyl, ; sec-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, neopentyloxycarbonyl, hexyloxycarbonyl, etc.], optionally substituted ar (lower) alkoxycarbonyl for example, mono or di or triphenyl (lower) alkoxycarbonyl which may be substituted with nitro [e.g. benzyloxy- carbonyl, 4-nitrobenzyloxycarbonyl, benzhydryloxy- carbonyl, trityloxycarbonyl, etc], or the like.
Suitable "leaving group" may be an acid residue such as halogen (e.g. chlorine, bromine, fluorine and iodine], sulfonyloxy (e.g. mesyloxy, tosyloxy, phenylsulfonyloxy, etc.] or the like.
The processes for preparing the starting compounds are explained in detail in the following.
Process A
Step 1
The compound [VI] or its salt can be prepared by - reacting a compound [IV] or its salt with a compound [Vv] or its salt.
Suitable salts of the compounds [IV], [V] and [VI] can be referred to the acid addition salts as exemplified for the compound (I].
This reaction is usually carried out in a conventional solvent such as water, an alcohol [e.g. methanol, ethanol, isopropyl alcohol, etc.], dioxane, tetrahydrofuran; N,N-dimethylformamide, methylene chloride, chloroform, tetrachloromethane, or any other conventional solvent which does not adversely affect this reaction, or a mixture thereof.
The reaction is carried out at ambient temperature, under warming or under heating, although the reaction temperature is not critical.
This reaction can also be conducted in the presence of an inorganic base, for example an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, or an alkali metal carbonate or hydrogen carbonate such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, or in the presence of an organic base, for example a tertiary amine such as triethylamine, pyridine or N,N-dimethylaniline.
This reaction can also be performed in the presence : of an alkali metal halide such as sodium iodide or potassium iodide.
Step 2
The compound [II] or its salt can be prepared by subjecting a compound [VI] or its salt to elimination reaction of the amino-protective group.
This elimination reaction can be carried out by a conventional manner, and the reaction mode [e.qg. hydrolysis, reduction, etc.] and the reaction conditions : [e.g. acid, base, catalyst, solvent, reaction temperature, etc.] of this reaction can be referred to those of the conventional elimination reaction of the amino-protective group.
Process B
Step 1
The compound [IX] or its salt can be prepared by reacting a compound [VII] or its salt with a compound [viIiI].
Suitable salts of the compounds [VII] and [IX] can be referred to the ones as exemplified for the compound [III].
This reaction is so-called Wittig reaction, and the reaction mode and reaction conditions can be referred to those of the conventional Witting reaction.
Step 2
The compound [III] or its salt can be prepared by subjecting a compound [VIII] or its salt to elimination reaction of the carboxy-protective group.
This elimination reaction can be carried out by a conventional manner, and the reaction mode [e.g. hydrolysis, reduction, etc.] and the reaction conditions [e.g. acid, base, catalyst, solvent, reaction temperature, etc.] of this reaction can be referred to those of the conventional elimination reaction of the carboxy protective group.
The compounds obtained by the above Processes 1, 2, 3, A and B can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation or the like.
It is to be noted that each of the object compound [I] and the starting compounds may include one or more stereoisomer due to asymmetric carbon atom(s) and/or carbon-carbon double bond (i.e. Z-isomer and E-isomer), and all such isomers and mixture thereof are included within the scope of this invention.
The new indolylpiperidine compound [11] and pharmaceutically acceptable salts thereof possess i antiallergic activity and/or anti-SRS-A activity and are -useful for a therapeutic treatment or prophylaxis of allergic disease, inflammation or the like, for example, allergic asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis [e.g. chronic urticaria, etc.], psoriasis, hepatitis, pancreatitis, arthritis, nephritis, inflammatory bowel disease, septic shock, arteriosclerosis, myocardial infarction, cerebral vasospasm Or the like.
The compound [I] and a pharmaceutically acceptable salt thereof of this invention can be used in the form of conventional solid, semisolid or liquid pharmaceutical preparations in admixture with conventional organic or inorganic carriers or excipients suitable for oral,
‘ X - 21 - parenteral or external application. The active ingredients may be admixed with conventional, nontoxic, pharmaceutically acceptable carriers having the form of, for example, tablets, pellets, capsules, patches, suppositories, solutions, emulsions or suspensions or any other form suitable for use. Usable carriers are not limited to any particular species. Thus, conventional carriers such as water, glucose, lactose, gum arabic, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch and urea and other carriers suitable for the manufacture of solid, semisolid or liquid preparations can be used. Furthermore, auxiliaries, stabilizers, thikening agents and colorants as well as aromas may be added.
The dose or therapeutically effective amount of the object compounds [I] of this invention may vary depending on the age and symptoms of each individual patient to be treated. Generally, the active ingredients are administered for disease treatment in a daily dose
Co of about 0.1-100 mg/kg, preferably 0.1-10 mg/kg.
In order to illustrate the usefulness of the object compound [I], the pharmacological test data of some representative compounds of the compound [I] are shown in.the following.
Test Compounds
Compound A : 1-[4-{5- (4-Hydroxy-3-methoxyphenyl) - (2E, 4E) - 2 ,4-pentadienoylamino}butyl]-4-(3-indolyl)- piperidine
Compound B : 1-[2-{5-(4-Hydroxy-3-methoxyphenyl) —- (2E,4E) -2, 4-pentadienoylamino}ethyl]- 4-(3-indolyl) piperidine
Compound C : 1-[2-{5- (4-Hydroxy-3,5-dimethoxyphenyl) - (2E,4E)-2,4-pentadienoylamino}ethyl]- 4- (3-indolyl)piperidine
Compound D : 1-[2-{5- (4-Acetoxy-3-methoxyphenyl)- (2E,4E)-2,4-pentadienoylamino}ethyl]-4-(3- indolyl)piperidine
Compound E : 1-[2-{5- (4-Acetoxy-3,5-dimethoxyphenyl)- (2E,4E)-2,4-pentadienoylamino}ethyl]-4- : (3-indolyl) piperidine
Compound F : 1-[2-{5-(3,5-Dichloro-4-hydroxyphenyl)-. (2E,4E)-2,4-pentadienoylamino}ethyl]-4- : © (3-indolyl)piperidine
Test 1 . Antagonistic .action on anaphylactic asthma in guinea pigs -
Male Hartley-strain guinea pigs weighing 305-400 g were used. These animals were sensitized by intravenous injection of 0.5 ml/animal of rabbit antiserum to egg-white albumin (PCA antibody titer 4,000). After 24 hours, the animals were housed individually in 5.3-liter plastic chambers. Using a commercial sprayer, a 5% egg-white albumin solution was sprayed in the form of an aerosol into each chamber at a rate of 0.16 ml/min for 2 minutes. Thirty minutes prior to the spraying of the egg-white albumin solution, the test compound was administered orally in varied concentrations. Each dosed group consisted of 5 animals. The prophylactic effect to anaphylaxis was expressed in terms of the EDg, value determined on the basis of the number of guinea pigs which had survived for not less than 2 hours after antigen spraying for each administration concentration of the test compound.
The values thus obtained are given in the following table.
Test Results
Test Compound Prophylactic Effect ED, : (mg/kg)
Test 2 - Anti-SRS-A activity
Peritoneal exudate cells were collected from glycogen-injected SD rats and adjusted to 1 x 107 cells/ml with Tyrode's solution. One milliliter of the cell suspension was incubated with indomethacin (10 ng/me) and each varied concentration of the test " compound for 10 minutes and, then, further incubated with ca't-ionophore (A23187, 1 ng/mf) for 10 minutes.
The supernatant was collected by centrifugation and the
SRS-A (slow-reacting substance of anaphylaxis) activity was determined in terms of contractility of the isolated guinea pig ileum in the presence of mepyramine, atropine and methysergide. :
The results were expressed in terms of the 50% inhibitory concentration to SRS-A synthesis or release from peritoneal exudate cells.
Test results
Inhibitory Concentration
Test Compound | ICso (ng/ml) = | em ce es
Co - 24 -
The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.
Preparation 1
A mixture of 4-(3-indolyl)piperidine (7.88 g),
N- (2-bromoethyl) phthalimide (10.0 g) and sodium hydrogen carbonate (3.64 g) in dry N,N-dimethylformamide (93 ml) was heated at 68-74°C for 4 hours. After cooling, the reaction mixture was poured into ice-water (1,000 ml). : The resulting precipitate was collected by filtration : and washed with methanol to give 1-(2-phthalimidoethyl)- 4- (3-indolyl) piperidine (5.53 g).
NMR (DMSO-d, §) : 1.3-3.4 (11H, m), 3.77 (2H, t,
J=6 .0Hz), 6.8-7.8 (5H, m), 7.89 (4H, m), 10.73 (1H, s)
MASS : 373 (M'), 213
Preparation 2
A mixture of 4- (3-indolyl) piperidine (7.47 g),
N- (3-bromopropyl) phthalimide (10.0 g) and sodium hydrogen carbonate (3.45 g) in dry N,N-dimethylformamide (88 ml) was heated at 70°C for 2 hours. After cooling, the reaction mixture was poured into water (880 ml) and extracted with a mixture of chloroform and methanol (10:1 V/V). The organic layer was washed with a saturated sodium chloride solution and dried over magnesium sulfate. The solvent was distilled off and the residue was subjected to column chromatography on silica gel (290 g) and eluted with a mixture of chloroform and methanol (20:1 V/V). The fractions containing the object compound were combined and concen- trated under reduced pressure. The residue was triturated with diethyl ether to give pale yellow crystals of 1-(3-phthalimidopropyl)-4-(3-indolyl)- piperidine (5.83 gq). a vo Cr . Co Ch yt Toe eet bo
IR (Nujol) : 3360, 1770, 1704, 1040, 735, 712 cm ©
NMR (DMSO-d, §) : 1.0-3.1 (13H, m), 3.67 (2H, t,
J=6 .0Hz), 6.8-7.6 (SH, m), 7.6-8.0 (4H, m), 10.63 (1H, s)
Preparation 3 1- (4-Phthalimidobutyl)-4- (3-indolyl) piperidine was obtained according to a similar manner to that of
Preparation 2.
IR (Nujol) : 3400-3300 (broad), 1770, 1700 (broad) cm
Preparation 4
A mixture of 1-(2-phthalimidoethyl)-4-(3-indolyl)- piperidine (6.3 g) and hydrazine monohydrate (2.2 g) in ethanol (250 ml) was refluxed for 70 minutes. After cooling, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure: The residue was treated with 5% sodium hydroxide solution (300 ml) and extracted with ethyl acetate (300 ml).
The organic layer was washed with a saturated sodium chloride solution and dried over magnesium sulfate.
The evaporation of solvent gave 1- (2-aminoethyl)-4- (3-indolyl) piperidine (3.74 gq).
IR (Nujol) : 3350, 1596, 953, 733 cm ©
NMR (CDCl,, §) : 1.5-3.4 (15H, m), 6.8-7.8 (5H, m), 8.5 (1H, br s)
MASS : 243 (M'), 213
Preparation 5
The following compounds were obtained according to a similar manner to that of Preparation 4. (1) 1- (3-Aminopropyl)-4- (3-indolyl) piperidine
IR (Nujol) : 3360, 3150, 1377, 1225 cm © oT - 26 -
NMR (DMSO-d, §) + 1.3-3.2 (17H, m), 6.7-7.7 (54, m), 10.67 (lH, s) (2) 1- (4-Aminobutyl) -4- (3-indolyl) piperidine
IR (Nujol) : 3390, 3150, 1110, 897, 736 cm = : NMR (DMSO-d, 8) : 1.0-3.2 (19H, m), 6.7-7.6 (SH, m), 10.67 (lH, s)
Preparation 6
A mixture of 4-hydroxy-3,5-dimethylbenzaldehyde (5 g), N,N-diisopropylethylamine (6.9 ml), (2-methoxy- ethoxy)methylchloride (4.26 ml) and 1,2-dichloroethane (65 ml) was refluxed for 5 hours. The reaction mixture was washed with water and dried over magnesium sulfate.
After removal of the solvent, the residue was subjected to column chromatography on silica gel and eluted with : a mixture of n-hexane and ethyl acetate (8:2 V/V). The fractions containing the object compound were combined and concentrated under reduced pressure to give 4-1 (2- methoxyethoxy)methoxy]-3;5-dimethylbenzaldehyde (6.54 g).
IR (neat) : 2900, 1690, 1600, 1130, 1100, 960, 740 cmt
NMR (CDCl 4, §) : 2.30 (6H, s), 3.32 (3H, s), 3.75, 4.0 (each 2H, m), 5.19 (2H, m), 7.60 (2H, s), 9.93 (1H, s)
Preparation 7
The following compounds were obtained according to a similar manner to that of Preparation 6. : (1) 3 '5-Diisopropyl-4- [ (2-methoxyethoxy)methoxyl- benzaldehyde
IR (Nujol) : 2950, 1690, 1595, 1585, 955 om 1 : 35 (2) 4-[(2-Methoxyethoxy)methoxy]-3-methylbenzaldehyde v v - 27 -
IR (neat) : 2950, 1690, 1600, 1590, 980 cmt
NMR (CDC1 4, §) + 2.31 (3H, s), 3.38 (3H, s), 3.6,3.8 (each, 2H, m), 5.41 (2H, s), 7.15-7.85 (3H, m), 9.90 (1H, s) (3) 3-Chloro-4-[(2-methoxyethoxy)methoxylbenzaldehyde
IR (neat) : 1700, 1595, 1570, 950 cm *
NMR (CDCl, 8) + 3.30 (3H, m), 3.6, 3.8 (each, 2H, m), 5.53 (2H, s), 7.2-7.9 (3H, m), 9.88 (lH, s) : (4) 3,5-Dichloro-4-[ (2-methoxyethoxy)methoxy]benzaldehyde
IR (neat) : 2900, 1705, 1590, 1560, 920, 810 em 1
NMR (CDC1 4, §) + 3.4 (3H, s), 3.6, 4.1 (each 2H, m), 5.38 (2H, s), 7.82 (2H, s), 9.85 (lH, s) (5) 3-Methoxy-2-[(2-methoxyethoxy)methoxylbenzaldehyde
IR (heat) : 1690, 1585, 950, 850, 785, 750 cmt
NMR (CDC1 5, 8) = 3.40 (3H, s), 3.6, 3.9 (each 2H, m), 3.95 (3H, s), 5.38 (2H, s), 7.2-7.6 (3H, m), 10.53 (1H, s)
MASS (m/e) : 240 (M'); 89, 59 (6) 3,5-Di-tert-butyl-4-[ (2-methoxyethoxy)methoxy]- benzaldehyde
IR (neat) : 1695, 1595, 945 cm ©
Preparation 8
To a stirred suspension of 60% sodium hydride (1.01 g) in dry tetrahydrofuran (60 ml), 80% triethyl 4-phosphonocrotonate (6.57 g) was added dropwise below 10°C under an inert atmosphere. After being stirred for 30 minutes, a solution of 4-[ (2-methoxyethoxy)methoxy]- 3,5-dimethylbenzaldehyde (5.0 g) in dry tetrahydrofuran (50 ml) was added thereto below 10°C. After stirring for 2 hours, the reaction mixture was concentrated under
: reduced pressure. The residue was dissolved in ethyl acetate (100 ml), washed with a saturated aqueous solution of sodium chloride and dried over magnesium sulfate. The solvent was distilled off and the residue was subjected to column chromatography on silica gel (130 g) and eluted with a mixture of n-hexane and ethyl acetate (7:3 V/V).
The fractions containing the object compound were combined and concentrated under reduced pressure to give a syrup of ethyl 5-[4- { (2-methoxyethoxy)methoxy}-3,5-dimethyl- phenyl]- (2E,4E)-2,4-pentadiencate (5.28 g).
IR (neat) : 2950, 1710, 1620, 1600, 970, 865 cm -
Preparation 9
The following compounds were obtained according to a similar manner to that of Preparation 8. (1) Ethyl 5-(3,5-diisopropyl-d4-{ (2-methoxyethoxy)methoxy}- + phenyl]- (2E,4E)~-2, 4-pentadiencate
IR (Nujol) : 1710, 1625, 1595, 965, 870 cm!
NMR (CDCl,, §) : 1.25 (12H, 4, J=8Hz), 1.31 (34, t, - J=8Hz), 3.45 (2H, sextet, J=8Hz), 3.43 (3H, s), 3.7, 4.0 (each 2H, m), 4.25 (2H, gq, J=8Hz), 5.03 (2H, s), 6.0 (1H, 4, J=15Hz), 6.8-7.7
Co (5H, m)
MASS (m/e) : 362 (M'), 89, 59 (base) (2) Ethyl 5- [4-{ (2-methoxyethoxy)methoxy}-3-methylphenyl]- (2E,4E)-2,4-pentadienoate
NMR (CDCI 4, §) + 1.31 (3H, t, J=8Hz), 2.25 (3H, s), 3.35 (3H, s), 3.7, 3.9 (each, 2H, m), 4.25 (2H, g, J=8Hz), 5.31 (2H, s), 5.95 (1H, 4, J=15Hz), 6.7-7.7 (6H, m)
MASS (m/e) : 320 (M'), 276, 89, 59 (3) Ethyl 5- [3-chloro-4-{ (2-methoxyethoxy)methoxy}-
Lo : IP Ta. aE wie et phenyl]-(2E,4E)-2, 4-pentadienocate
IR (neat) : 2900, 1710, 1630, 1600, 1055, 980 cmt
NMR (CDC1,, §) 1.31 (3H, t, J=8Hz), 3.35 (3H, s), 3.7, 3.9 (each 2H, m), 4.28 (2H, gq, J=8Hz), 5.33 (2H, s), 5.97 (1H, 4, J=15Hz), 6.7-7.7 (6H, m) (4) Ethyl 5-[3,5-dichloro-4-{ (2-methoxyethoxy)methoxy}- phenyl]- (2E, 4E)-2, 4-pentadienoate mp : 67-69°C (recrystallized from a mixture of toluene and ethyl acetate (8:1))
IR (Nujol) : 1710, 1630, 1545, 1000, 925, 860, 800 cm!
NMR (CDC1,, 8) + 1.30 (3H, t, J=8Hz), 3.38 (3H, s), 3.6, 4.1 (each 2H, m), 4.23 (2H, gq, J=8Hz), 5.29 (2H, s), 6.03 (1H, 4, J=15Hz), 6.6-7.7 (5H, m)
MASS (m/e) : 376 (M+2), 375 (M+l), 374 (M7), 89 (base) (5) Ethyl 5- [3-methoxy-2-{ (2-methoxyethoxy)methoxy}- - phenyl]-(2E,4E)-2,4-pentadienoate mp : 48-49°C (recrystallized from a mixture of n-hexane and diisopropyl ether)
IR (Nujol) : 1720, 1623, 1000, 945, 850 cm”!
NMR (CDCI ,, §) : 1.35 (3H, t, J=7Hz), 3.4 (3H, s), 3.6, 3.9 (each 2H, m), 3.86 (3H, s), 4.27 (2H, q, J=7Hz), 5.25 (2H, s), 6.03 (1H, 4, L
J=15Hz), 6.6-7.7 (6H, m) (6) Ethyl S-[4-methoxy-3-{(2-methoxyethoxy)methoxy}- phenyl]-(2E,4E)-2,4-pentadienocate
IR (neat) : 1710, 1625, 1600, 1000 cm ©
NMR (CDCL 5, §) : 1.36 (3H, t, J=7Hz), 3.4 (3H, s), 3.6, 3.9 (each 2H, m), 3.90 (3H, s),
4.25 (2H, q, J=7Hz), 5.31 (2H, s), 5.98 (1H, d,
J=15Hz), 6.6-7.8 (6H, m) (7) Ethyl 5-(3,5-di-tert-butyl-4-{ (2-methoxyethoxy)- : methoxylphenyl]- (2E,4E)-2,4-pentadienoate
IR (neat) : 1710, 1625 —
Preparation 10
To a stirred solution of ethyl 5-[4-{(2-methoxy- ethoxy)methoxy}-3,5-dimethylphenyl]- (2E,4E)~2,4- _ pentadienoate (5.28 g) in methanol (55 ml) was added a solution of sodium hydroxide (6.32 g) in water (18 ml) below 20°C. After being stirred for an hour, the reaction, mixture was concentrated under reduced pressure. The residue was dissolved in water (200 ml) and adjusted to pH 4 with 10% hydrochloride solution. The resulting precipitate was collected by filtration and washed with water to give yellowish powder of 5-[4-{ (2-methoxyethoxy)- methoxy}-3,5-dimethylphenyl]- (2E,4E)-2,4-pentadienoic acid (4.13 gq). mp : 88-91°C
IR (Nujol) : 2650, 1675, 1615, 1595, 1000, 970, 860 cm ©
NMR (CDCl 5, §) : 2.30 (6H, s), 3.43 (3H, s), 3.7, 4.0 (each 2H, m), 5.05 (2H, s), 5.95 (1H, d, J=15Hz), 6.75-7.8 (5H, m), 10.25 (1H, m)
MASS (m/e) : 306 (M7), 89 (base)
Preparation 11
The following compounds were obtained according to a similar manner to that of Preparation 10. (1) 5-(3,5-Diisopropyl-4-{ (2-methoxyethoxy)methoxy}- ; phenyl]-(2E,4E)-2,4-pentadienoic acid mp : 96-113°C : Cy Cov tree : .
. "a. - 31 -
IR (Nujol) : 2600, 1685, 1615, 1595, 1100, 1080, 970 cmt
NMR (CDCL 4, §) «+ 1.25 (12H, 4, J=8Hz), 3.45 (2H, sext, J=8Hz), 3.43 (3H, s), 3.7, 4.0 (each 2H, m), 5.03 (2H, s), 6.0 (1H, 4, J=15Hz), 6.8-7.8 (5H, m), 10.13 (lH, m)
MASS (m/e) : 362 (M'), 89, S59 (base) (2) 5-[4-{(2-Methoxyethoxy)methoxy}-3-methylphenyl]- (2E,4E)-2,4-pentadienoic acid : mp : 117-119°C
IR (Nujol) : 2600, 1670, 1600, 1000, 930 cm
NMR (CDCl,, §) : 2.26 (3H, s), 3.30 (3H, s), 3.6, 3.9 (each, 2H, m), 5.32 (2H, s), 5.98 1S (1H, d, J=15Hz), 6.7-7.8 (6H, m), 8.7 (lH, m) (3) 5-(3-Chloro-4-{ (2-methoxyethoxy)methoxy}phenyl]- (2E,4E)-2,4-pentadienoic acid mp : 130-135°C
IR (Nujol) : 2600, 1680, 1615, 1590, 1050, 995 cm '
NMR (CDCl 5, §) + 3.30 (3H, s), 3.6, 3.9 (each 2H, m), 5.38 (2H, s), 6.01 (1H, 4, J=15Hz), 6.7-7.7 (6H, m), 9.7 (1H, m) (4) 5-(3,5-Dichloro-4-{ (2-methoxyethoxy)methoxy}- phenyl]- (2E,4E)-2, 4-pentadienoic acid mp : 116-120°C
IR (Nujol) : 2600, 1690, 1630, 990, 905, 805 a
NMR (cpcl 4, §) : 3.40 (3H, s), 3.6, 4.1 (each 2H, m), 5.29 (2H, s), 6.05 (1H, 4, J=15Hz), 6.7-7.7 (5H, m), 9.65 (lH, br)
MASS (m/e) : 348 (M+2), 346 (M'), 89, 59 (base) (5) 5-[3-Methoxy-2-{ (2-methoxyethoxy)methoxy}phenyl]- (2E,4E)-2,4-pentadienoic acid mp : 140-144°C
IR (Nujol) : 2600, 1690, 1610, 1050, 955 cm
NMR (CDCl, §) : 3.33 (3H, s), 3.5, 3.8 (each 2H, m), 3.80 (3H, s), 5.15 (2H, s), 5.93 (lH, 4,
J=15Hz), 6.7-7.7 (6H, m), 9.5 (1H, br) (6) 5-[4-Methoxy-3-{ (2-methoxyethoxy) methoxy }phenyl]- (2E,4E)-2,4-pentadienoic acid mp : 121-125°C
IR (Nujol) : 2600, 1670, 1620, 1590 emt
NMR (CbClgy, §) : 3.35 (3H, s), 3.55, 3.90 (each 2H, m), 3.86 (3H, s), 5.30 (2H, s), 5.92 (1H, d, J=15Hz), 6.7-7.7 (6H, m), 10.2 (1H, br) (7) 5-(3,5-Di-tert-butyl-4-{ (2-methoxyethoxy)methoxy}- phenyl]- (2E,4E)-2,4-pentadienoic acid
IR (Nujol) : 2650, 1680, 1620, 970 em”!
NMR (cpCly, §) «2 1.46 (18H, s), 3.42 (3H, 8s); 3.66, 3.96 (each 2H, m), 5.0 (2H, s)., 5.97 (1H, 4, J=15.5Hz), 6.6-7.7 (5H, m), 9.2 (1H, br)
Example 1
To a stirred mixture of 3- [3-methoxy-4-{ (2-methoxy- ethoxy) methoxy }phenyl]- (E) -propenoic acid (1.75 g) and triethylamine (1.81 ml) in dry N,N-dimethylformamide (10 ml) was added slowly diphenyl phosphinic chloride (1.47 g) at -10 to -15°C under an inert atmosphere.
After being stirred for 30 minutes, a solution of 1- (2-aminoethyl)-4- (3-indolyl) piperidine (1.5 g) in dry
N,N-dimethylformamide (10 ml) was added slowly to the reaction mixture at -10°C. After being stirred for 1 hour at ambient temperature, the reaction mixture was poured into ice-water (200 ml) and extracted with fe chloroform (100 ml). The extract was washed with a saturated sodium chloride solution and dried over magnesium sulfate. The solvent was distilled off and the residue was subjected to column chromatography on silicagel (47 g) and eluted with a mixture of chloroform and methanol (10:1). The fractions containing the object compound were combined and concentrated under reduced pressure to give syrup of 1-[2-(3-[3-methoxy-4- { (2-methoxyethoxy) methoxy}phenyl]- (E) -propenoylamino]- ethyl]-4-(3-indolyl) piperidine (2.8 gq).
NMR (CDC 4, §) + 1.6-3.3 (11H, m), 3.37 (3H, s), 3.55 (4H, m), 3.85 (2H, m), 3.89 (34, s), 5.32 (2H, s), 6.35 (1H, 4, J=15.0Hz), 6.52 (lH, br s), 6.9-7.8 (8H, m), 7.57 (1H, 4, J=15.0Hz), 8.25 (lH, br s)
Example 2
The following compounds were obtained according to a similar manner to that of Example 1. (1) 1-{2-[5-[3-Methoxy-4-{ (2-methoxyethoxy)methoxy}- phenyl]- (2E,4E)-2,4-pentadienoylaminojethyl]-4- (3- indolyl) piperidine
IR (Nujol) : 3300, 1660, 1260, 1092, 990, 744 cm *
NMR (CDCl, §) : 1.6-3.3 (11H, m), 3.35 (3H, s), 3.54 (4H, m), 3.84 (2H, m), 3.86 (3H, s), 5.30 (2H, s), 6.07 (1H, 4, 15.0Hz), 6.70-7.80 (12H, m), 9.30 (1H, s)
MASS : 533 (M'), 213 (2) 1- [3-[5- [3-Methoxy-4-{ (2-methoxyethoxy) methoxy} - phenyl]- (2E,4E)-2,4-pentadienoylamino]propyl]-4- (3-indolyl) piperidine
NMR (CDCl 4, §) : 1.5-3.6 (15H, m), 3.36 (3H, s)., 3.6 (2H, m), 3.87 (3H, s), 3.90 (2H, m), 5.35 (2H, s), 6.02 (lH, 4, J=14.4Hz), 6.6-7.9 (12H, m), 8.55 (1H, s)
MASS : 547 (M1)
(3) 1- [4- [5- [3-Methoxy-4-{ (2-methoxyethoxy)methoxy}- : phenyl]- (2E,4E)-2, 4-pentadienoylamino]butyl]-4-(3- : indolyl) piperidine
IR (Nujol) : 3400, 3200 (broad), 1650, 1377, 1260 cmt
NMR (CDCl 5, §) : 1.3-3.4 (17H, m), 3.33 (3H, Ss), 3.55 (2H, m), 3.80 (5H, br s), 5.27 (2H, s), 6.11 (1H, 4, J=15.0Hz), 6.5-8.0 (12H, m), 9.23 (lH, s)
Mass : 561 (MV) : (4) 1-[2-{5-(3,4-Dimethoxyphenyl)-(2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl) piperidine mp : 196-198°C (recrystallized from ethanol) :
IR (Nujol) : 3280, 1640, 1610, 1590, 1550, 1510 a}
NMR (DMSO-d, §) + 1.4-3.5 (13H, m), 3.78 (3H, s), 3.81 (34, s), 6.15 (1H, 4, J=15.0Hz), : 6.8-7.6 (11H, m), 7.99 (lH, br t), 10.75 (1H, br s)
MASS : 459 (M1), 213
Elemental analysis : C,gH33N303
Calcd. : C 73.18, H 7.24, N 9.14
Co Found : C 73.84, H 7.42, N 8.72 (5s) 1-[2-{5-(3,4,5-Trimethoxyphenyl)- (2E,4E)-2,4~ pentadienoylamino}ethyl]-4-(3-indolyl)piperidine mp : 86-100°C
IR (Nujol) : 3250, 1650, 1610, 1580 cm ©
NMR (DMSO-d, §) + 1.4-3.6 (13H, m), 3.70 (3H, s), 3.83 (6H, s), 6.19 (1H, 4, J=15.0Hz)}, 6.7-7.7 (L0H, m), 8.02 (lH, br t), 10.74 (lH, br s)
Mass : 489 (M') 289, 213 ~ Elemental analysis : C,gH35N 30," 3/4H,0 i caled. : C 69.23, H 7.31, N 8.35 - 35 Found : C 69.38, H 7.08, N 8.40
Sane a ee
, . - 35 - (6) + 1-[(2-{3- (4-Hydroxy-3-methoxyphenyl)- (E)-propenoyl- aminolethyl]-4- (3-indolyl) piperidine mp : 115-135°C
IR (Nujol) : 3300 (broad), 1655, 1588, 1512 cm - (7) 1-[2-{5-(4-Hydroxy-3-methoxyphenyl)-(2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine mp : 115-131°C
IR (Nujol) : 3330 (broad), 1660, 1377 cm - : (8) 1-[3-{5-(4-Hydroxy-3-methoxyphenyl)-(2E,4E)-2,4- pentadienoylamino}propyl]l-4-(3-indolyl)piperidine mp : 150-170°C
IR (Nujol) : 3400, 3200 (broad), 1638, 1580 cm © (9) 1-(4-{5-(4-Hydroxy-3-methoxyphenyl)- (2E,4E)-2,4- pentadienoylaminol}butyl]-4- (3-indolyl)piperidine mp : 150-170°C
IR (Nujol) : 3200 (broad), 1640, 1580, 1270, 735 cm © - (10) 1-[2-[5-[3,4-Bis{ (2-methoxyethoxy)methoxy}phenyl]- (2E,4E)-2,4-pentadienoylamino]ethyl]-4-(3-indolyl)~ piperidine
This compound was used as a starting compound of
Example 7- (4) without purification. (11) 1-[2-[5-[3,5-Dimethoxy-4-{ (2-methoxyethoxy)methoxy}- phenyll- (2E,4E)-2,4-pentadienoylamino]ethyl]-4-(3- 30. indoyl) piperidine
IR (Nujol) : 3300, 1650, 1610, 1580, 1125, 990, 960, 845, 745 cm © (12) 1-[3-[5-[3,5-Dimethoxy-4-{ (2-methoxyethoxy)methoxy}- phenyl]- (2E,4E)-2,4-pentadienoylamino}propyl]-4- (3-indolyl)piperidine
Co - 36 -
IR (neat) : 3300, 3000, 2990, 1650, 1615, 1580, 1130, 990, 960, 850 cm (13) 1-[4- [5- [3,5-Dimethoxy-4-{ (2-methoxyethoxy) methoxy }- phenyl]- (2E, 4E)-2, 4-pentadienoylamino]butyl]-4-(3- indolyl) piperidine
IR (neat) : 2900, 1650, 1610, 1580, 1550, 1120, 960, 850, 740 cm ©
C10 (14) 1-[2-[5-[4-{(2-Methoxyethoxy)methoxy}-3,5- dimethylphenyl]- (2E,4E)-2,4-pentadienoylamino]ethyl]- 4-(3-indolyl)piperidine mp : 163-164°C (recrystallized from ethyl acetate)
IR (Nujol) : 3450, 3300, 1645, 1615, 990, 970 cm =
NMR (DMSO-d, 6) : 1.5-2.3 (6H, m), 2.34 (6H, s), 2.5-3.1 (7H, m), 3.25 (3H, s), 3.5, 3.8 (each 2H, m), 5.05 (2H, s), 6.15 (1H, d, J=15Hz), 6.8-7.7 (10H, m), 8.03 (1H, m), 10.7 (1H, m)
MASS (m/e) : 531 (M7), 213 (base) (15) 1-[2-[5-[3,5-Diisopropyl-4-{ (2-methoxyethoxy)- methoxy }phenyl]- (2E,4E)-2, 4-pentadienoylamino]- ethyl]-4-(3-indolyl)piperidine
IR (neat) : 1660, 1650, 1615, 970 cm © (16) 1-[2-[5- [4-{ (2-Methoxyethoxy)methoxy}-3-methyl- phenyl]- (2E,4E) -2, 4-pentadienoylaminojethyl]-4- (3- indolyl) piperidine mp : 140-144°C
IR (Nujol) : 3470, 3280, 1640, 1610, 1595, 1000, 980 cm
NMR (CDCL 5, §) : 1.6-3.2 (13H, m), 2.25 (3H, s), 3.38 (3H, s), 3.6, 3.8 (each, 2H, m), 5.32 (2H, s), 5.96 (lH, 4, J=15Hz), 6.2-7.8 (11H, mm), 8.25 (lH, m)
MASS (m/e) : 517 (MT), 213 (base)
(17) 1-1[2-[5-([3-Chloro-4-{(2-methoxyethoxy)methoxy}- phenyl]- (2E,4E)-2,4-pentadienoylaminojethyl]-4~ (3-indolyl) piperidine
IR (Nujol) : 3450, 3300, 1645, 1610, 1050, 990 cm ©
NMR (DMSO-d, §) + 1.5-2.5 (6H, m), 2.8-3.2 (7H, m), 3.65 (34, s), 3.6, 3.8 (each 2H, m), 5.39 (2H, s), 6.10 (lH, 4, J=15Hz), 6.8-7.9 (11H, m), 8.05 (1H, m), 10.75 (1H, m)
MASS (m/e) : 537, 213 (base) (18) 1-[2-{5- (3,4-Dihydroxyphenyl)- (2E,4E)-2,4~ pentadienoylamino}ethyl]-4- (3-indolyl)piperidine
IR (Nujol) : 3400, 3350, 1650, 1585, 1520 cm
MASS (m/e) : 431 (M'), 213 (base) (19) 1-[2-{5- (4-Hydroxy-3,5-dimethoxyphenyl)- (2E, 4E) - 2,4-pentadienoylamino}ethyl]-4- (3-indolyl)piperidine
IR (Nujol) : 3420, 1665, 1650, 1620, 1590, 1530, 1515, 1120 cm ©
MASS (m/e) : 475 (M'), 213 (20) 1-[4-{5- (4-Hydroxy-3,5-dimethoxyphenyl)- (2E,4E)- 2, 4-pentadienoylamino}butyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3250, 1640, 1600, 1540, 1510, 1130, 1110, 810 cm (21) 1- [3-{5- (4-Hydroxy-3,5-dimethoxyphenyl)- (2E,4E) - 2, 4-pentadienoylamino}propyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3420, 1658, 1610, 1575, 1550, 1510, 1120 em 1
MASS (m/e) : 489 (MT), 239, 233, 213 (base), 197 (22) 1- [2-{5- (4-Acetoxy-3-methoxyphenyl)- (2E,4E)-2,4~ : pentadienoylamino}ethyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3440, 3250, 1760, 1655, 1620, 1560, 1505 cm ©
MASS (m/e) : 487 (M'), 213 (base) (23) 1-[2-{5- (3-Methoxy-4-propionyloxyphenyl)- (2E,4E)- 2,4-pentadienoylamino}ethyl]-4-(3-indolyl) piperidine
IR (Nujol) : 3430, 3250, 3060, 1750, 1655, 1620, 1560 cm
MASS (m/e) : 501 (M'), 213 (base) (24) 1- [2- {5- (4-Ethoxycarbonyloxy-3,5-dimethoxyphenyl)- (2E,4E)-2,4-pentadienoylamino}ethyl]-4- (3-indolyl)- piperidine
IR (Nujol) : 3360, 3300, 1750, 1640, 1590, 1130, 1000, 735 cm *
MASS (m/e) : 547 (M'), 228, 213 (base) (25) 1-[4-{5- (4-Ethoxycarbonyloxy-3,5-dimethoxyphenyl)- (2E,4E)-2,4-pentadienoylamino}butyl]-4- (3-indolyl)- piperidine : IR (Nujol) : 3380, 3250, 1750, 1655, 1620, 1595, 1555, 1130, 1050, 1000, 735 emt : MASS (m/e) : 575 (M'), 531, 503, 285, 233, 213 (base) (26) 1-[2-{5- (4-Hydroxy-3,5-dimethylphenyl)- (2E,4E)- 2,4-pentadienoylaminolethyl]}-4-(3-indolyl)- piperidine
IR (Nujol) : 3300, 1640, 1590, 1545, 990, 860 cm 1
MASS (m/e) : 443 (M'), 213 (base) (27) 1-[2-{5- (4-Hydroxy-3,5-diisopropylphenyl)- (2E,4E)- 2, 4-pentadienoylamino}ethyl]-4- (3-indolyl)- piperidine
IR (Nujol) : 3400, 3300, 1650, 1630, 1585, 995, 870 cm ©
MASS (m/e) : 499 (M'), 226, 213 (base) bol
(28) 1-{2-{5-(4-Hydroxy-3-methylphenyl)-(2E,4E)-2,4- pentadienoylamino}ethyl]~-4-(3-indolyl)piperidine
IR (Nujol) : 3200, 1640, 1575, 1550, 1000 —
MASS (m/e) : 429 (M'), 213 (base) (29) 1-[2-{5-(3-Chloro-4-hydroxyphenyl)- (2E,4E)-2,4- pentadienoylaminol}ethyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3420, 1650, 1590, 1000 em *
MASS (m/e) : 449 (M'), 213 (base) : (30) 1-[2-{5-(4-Acetoxy-3,5-dimethoxyphenyl)- (2E,4E)- 2,4-pentadienoylamino}ethyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3380, 3320, 1755, 1650, 1620, 1595, 990, 745 cm
MASS (m/e) : 517 (M'), 213 (base) (31) 1-[2-[5-[3,5-Dichloro-4-{ (2-methoxyethoxy) methoxy }- phenyl]- (2E,4E)-2,4-pentadienoylaminolethyl]-4- (3-indolyl) piperidine
IR (neat) : 1655, 1610, 995 cm © : (32) 1-[2-[5-[3-Methoxy-2-{ (2-methoxyethoxy)methoxy}- phenyl]- (2E,4E)-2,4-pentadienoylaminolethyl]-4- (3-indolyl) piperidine
IR (neat) : 1650, 1610, 1000, 960 cm © (33) 1-[2-[5- [4-Methoxy-3-{(2-methoxyethoxy)methoxy}- phenyl]-(2E,4E)-2,4-pentadienoylaminojethyl]-4- oe (3-indolyl) piperidine mp : 135-136°C (recrystallized from ethyl acetate)
IR (Nujol) : 3260, 1640, 1615, 1595, 1550, 1510 emt
NMR (DMSO-d, §) : 3.75 (3H, s), 5.23 (2H, s), 6.11 (1H, 4, J=15Hz), 6.7-7.6 (11H, m), 7.96 (lH, t like), 10.7 (1H, br)
MASS (m/e) : 533, 445, 333, 213 (base)
(34) 1-[2-[5-[3,5-Di-tert-butyl-2-{ (2-methoxyethoxy)- methoxy }phenyl]- (2E,4E)-2,4-pentadienoylamino}- ethyl]-4-(3-indolyl)piperidine mp : 98-103°C (recrystallized from ethanol)
IR (Nujol) : 3300, 1650, 1600, 970 cm!
NMR (CDC1 5, §) : 1.42 (18H, s), 1.6-2.3 (6H, m), 2.53 (2H, t, J=7Hz), 2.8 (3H, m), 3.35 (3H, s), 3.5 (2H, m), 3.66, 3.96 (each 2H, m), 4.93 (24, s), 5.95 (1H, 4, J=15.5Hz), 6.17 (1H, t like), 6.6-7.7 (10H, m), 8.2 (1H, s) (35) 1-[2-1{5- (3,5-Di-tert-butyl-4-hydroxyphenyl)- (2E,4E)~ 2, 4-pentadienoylamino}ethyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3550, 3300, 3230, 1650, 1610, 1590, 1000 cm
MASS (m/e) : 527 (M'), 226, 213 co (36) 1- [2-{5- (3,5-Dichloro-4-hydroxyphenyl)- (2E,4E)~ 2, 4-pentadienoylamino}ethyl]-4-(3-indolyl)- piperidine
MASS (m/e) : 485 (M+2), 483 (M7), 213 (base) (37) 1- [2-{5- (2-Hydroxy-3-methoxyphenyl)- (2E,4E)- 2, 4-pentadienoylamino}ethyl]-4-(3-indolyl) piperidine : 25 IR (Nujol) : 3400, 3240, 1650, 1605, 1600, 1530, 1090, 1005 cmt : MASS (m/e) : 445 (M1), 226, 213 (base) (38) 1-[2-{5- (3-Hydroxy-4-methoxyphenyl)- (2E,4E)-2,4~ pentadienoylamino}ethyl]-4-(3-indolyl)piperidine
IR (Nujol) : 3350, 1650, 1615, 1590 ont
MASS (m/e) : 445 (M'), 213 (base)
L (39) 1-[2- [5- (3, 4-bis (Ethoxycarbonyloxy) phenyl} = (2E, 4E) ~ 2,4-pentadienoylaminolethyl]-4- (3-indolyl)piperidine
IR (Nujol) : 3500, 3350, 1775, 1650, 1620, 1000 cm 1
MASS (m/e) : 529 (M'-d6), 457, 285 (base), 213
Example 3
To a solution of 1-[2-(5-[3,5-di-tert-butyl-4-{(2- methoxyethoxy) methoxy }phenyl]- (2E,4E)~2,4-pentadienoyl- amino]ethyl]-4-(3-indolyl)piperidine (0.5 g) in methanol (5 ml) was added dropwise methanesulfonic acid (0.26 ml) at 18-25°C. After 2 hours the reaction mixture was adjusted to pH 7.5 with 2N-sodium hydroxide and then poured into saturated sodium bicarbonate solution (50 ml). The resulting precipitate was collected and washed with water. The precipitate was subjected to column chromatography on silica gel and eluted with a mixture of chloroform and methanol (20:1, V/V). The fractions containing the object compound were combined and concentrated under reduced pressure. The residue was recrystallized from 1,4-dioxane, to give white crystals of 1-[2-{5-(3,5-di-tert-butyl-4-hydroxyphenyl)- (2E,4E)- 2,4-pentadienoylaminolethyl]-4-(3-indolyl) piperidine . (0.28 gq). mp : 108-115°C
IR (Nujol) : 3550, 3300, 3230, 1650, 1610, 1590, 1000 emt
NMR- (CDCly, §): 1.43 (18H, s), 1.6-2.3 (6H, m), 2.53 (2H, t, J=7Hz), 2.7-3.2 (3H, m), 3.45 (2H, m), 5.33 (1H, s), 5.93 (1H, 4, J=15.5Hz), 6.15 (1H, t like), 6.65-7.7 (10H, m), 8.16 (lH, s)
MASS (m/e) : 527 (M'), 226, 213
Example 4
To a stirred solution of 1-[2-[5-[3,5-dimethoxy-4- { (2-methoxyethoxy) methoxy }phenyl]- (2E,4E)-2,4- pentadienoylaminolethyl]-4- (3-indolyl)piperidine (10.0 q)
in methanol (100 ml) was added slowly methanesulfonic acid (2.3 ml) at ambient temperature. After stirring for 2 hours, the reaction mixture was adjusted to pH 7.2 with aqueous 2N sodium hydroxide solution, and poured into a solution of 4.5 g of sodium bicarbonate in 500 ml of water. After stirring for 30 minutes, the resulting precipitate was collected by filtration and washed with 100 ml of water. The residue was subjected to column chromatography on silica gel and eluted with a mixture of chloroform and methanol. The fractions containing the : : object compound were combined and concentrated under reduced pressure. The residue was recrystallized from ethanol to give 1- [2-{5- (4-hydroxy-3,5-dimethoxyphenyl)- (2E,4E)-2, 4-pentadienoylamino}ethyl]-4~(3-indolyl)- oo 15 piperidine (6.69 g). mp : 199-202°C (dec.)
IR (Nujol) : 3420, 1665, 1650, 1620, 1590, 1530, 1515, 1120 cm ©
NMR (DMSO-d, §) : 1.5-2.4 (7H, m), 2.7-3.5 (6H, m}, 3.81 (6H, s), 6.15 (lH, 4, J=14Hz), 6.8-7.8 (10H, m), 8.0 (1H, t like), 8.68 (lH, m), 10.75 (1H, s)
MASS (m/e) : 475 (M'), 213
Elemental analysis : C,gH33N30, calcd. : C 70.71, H 6.99, N 8.83
Found : C 70.34, H 6.56, N 8.65
Example 5
A mixture of 1-[3-[5-[3,5-dimethoxy-4-{ (2-methoxy- ethoxy) methoxy }phenyl]- (2E,4E)~2, 4-pentadienoylamino]- propyl]-4-(3-indolyl)piperidine (L.67 g) and p-toluene- sulfonic acid monohydrate (0.64 g) in methanol (33 ml) was refluxed for 30 minutes under an inert atmosphere.
Upon cooling to ambient temperature, the mixture was added dropwise to an aqueous sodium carbonate solution.
The resulting powder was subjected to column chromato- graphy on silica gel and eluted with a mixture of chloroform and methanol (10:1 V/V). The fractions containing the object compound were combined and concentrated under reduced pressure. The obtained residue was recrystallized from a mixture of ethanol and water (7:3 V/V) to give 1-[3-{5-(4-hydroxy-3,5- dime thoxyphenyl)- (2E,4E)~-2,4-pentadienoylamino}propyl]- 4- (3-indolyl) piperidine (0.51 g). mp : 176-179°C (recrystallized from ethanol - water (8:2, v/V))
IR (Nujol) : 3420, 1658, 1610, 1575, 1550, 1510, 1120 cm ©
NMR (DMSO-d, §) + 1.4-2.5 (9H, m), 2.6-3.5 (6H, m), 3.79 (6H, s), 6.10 (1H, 4, J=15Hz), 6.7-7.7 (10H, m), 8.05 (lH, t like), 8.7 (1H, m), 10.72 (1H, s) :
MASS (m/e) : 489 (M'), 239, 233, 213 (base), 197
Elemental analysis : C,gH35N30, caled. : C 71.14, H 7.20, N 8.58
Found : C 70.79, H 7.12, N 8.57
Example 6
A mixture of 1-[2-[3-[3-methoxy-4-{(2-methoxyethoxy)- methoxy }phenyl]- (E)-propenoylaminojlethyl]-4-(3-indolyl)- piperidine (2 g) and p-toluenesulfonic acid monohydrate (1.05 g) in methanol (40 ml) was refluxed for 30 minutes ) under an inert atmosphere. After the solvent was removed under reduced pressure, the residue was treated with water (100 ml), adjusted to pH 10.0 with a sodium carbonate solution and extracted with ethyl acetate.
The extract was washed with a saturated sodium chloride solution and dried over magnesium sulfate. After removal of the solvent, the residue was subjected to column chromatography on silica gel (31 g) and eluted with a mixture of chloroform and methanol (8:1 V/V). The fractions containing the object compound were combined and concentrated under reduced pressure to give 1-(2- (3- (4-hydroxy-3-methoxyphenyl)- (E) ~propenoylamino}ethyl]- 4-(3-indolyl)piperidine (0.89 g). : mp : 115-135°C = IR (Nujol) : 3300 (broad), 1655, 1588, 1512 cmt : NMR (DMSO-d, §) : 1.5-3.6 (14H, m), 3.83 (3H, s), y 6.50 (1H, d, J=15.0Hz), 6.7-7.7 (9H, m), 7.83 (1H, br t), 10.70 (1H, s) © Mass : 419 (M'), 213
Elemental analysis : C, gH, gN304"1/2H,0
Caled. : C 70.00,H 7.06, N 9.80
Found : C 70.18,H 6.92, N 9.85
Example 7 :
The following compounds were obtained according to similar manners to those of Examples 3 to 6. (1) 1-[2-{5- (4-Hydroxy-3-methoxyphenyl)- (2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine : mp : 115-131°C
IR (Nujol) : 3330 (broad), 1660, 1377 gt
NMR (DMSO-d, §) + 1.5-3.6 (13H, m), 3.82 (3H, s), 6.07 (1H, 4, J=15.0Hz), 6.6-7.6 (8H, m), 7.90 (1H, br t), 9.20 (lH, s), 10.68 (lH, s)
MASS : 445 (M7), 213
Elemental analysis : C, Hy N304°1/2H50 calcd. : C 71.34, H 7.10, N 9.24
Found : C 71.15, H 6.87, N 9.19 ’ (2) 1- [3-{5- (4-Hydroxy-3-methoxyphenyl)- (2E, 4E)-2,4~ pentadienoylamino}propyl]-4- (3-indolyl) piperidine mp : 150-170°C
IR (Nujol) : 3400, 3200 (broad), 1638, 1580 emt in
NMR (DMSO-d, §) + 1.5-3.8 (15H, m), 3.86 (3H, s), 4.20 (1H, broad), 6.15 (1H, 4d, J=14.0Hz), 6.6~7.8 (11H, m), 8.26 (lH, br s), 10.82 (1H, s)
MASS : 459 (M1), 213
Elementan analysis : C,gHy3N304-1/2CHCL4-1/2C, HOC, Hy
Calcd. : C 65.85, H 6.97, N 7.55
Found : CC 65.67, H 7.18, N 7.87 (3) 1-{4-{5-(4-Hydroxy-3-methoxyphenyl)-(2E,4E)-2,4~- pentadienoylamino}butyl]-4-(3-indolyl)piperidine mp : 150-170°C
IR (Nujol) : 3200 (broad), 1640, 1580, 1270, 735 —
NMR (DMSO-d, §) «+ 1.2-3.7 (17H, m), 3.80 (3H, s), 6.07 (lH, 4, J=15.0Hz), 6.6-7.8 (11H, m), 8.10 (1H, s), 9.25 (1H, s), 10.82 (1H, s)
MASS : 473 (M'), 213
Elemental analysis : C,gH35N;04°1/2CHCL 5-1/2C, H 0C Hy calcd. : C 66.33, H 7.16, N 7.37
Found : C 66.02, H 7.47, N 7.33 (4) 1-({2-{5-(3,4-Dihydroxyphenyl)-(2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine mp : 138-158°C (dec.) (recrystallized from ethanol- water (8:2 V/V))
IR (Nujol) : 3400, 3350, 1650, 1585, 1520 cm
NMR (DMSO-d, §) : 1.5-3.6 (13H, m), 6.13 (1H, 4,
J=15Hz), 6.63-7.70 (11H, m), 7.93 (lH, m), 10.73 (1H, br)
MASS (m/e) : 431 (M'), 213 (base)
Elemental analysis : C,gHygN30476/5 ethanol calcd. : C 70.07, H 7.49, N 8.63
Found : C 69.77, H 7.39, N 8.67 (5) 1-[4-{5- (4-Hydroxy-3,5-dimethoxyphenyl)- (2E,4E)- 2,4-pentadienoylaminolbutyl]-4-(3-indolyl)- piperidine
' “ - 46 - .
IR (Nujol) : 3250, 1640, 1600, 1540, 1510, 1130, 1110, 810 cm * (6) 1-[2- {5- (4-Hydroxy-3,5-dimethylphenyl)- (2E,4E)-2, 4~ pentadienoylamino}ethyl]-4-(3-indolyl)piperidine mp : 125-135°C (recrystallized from ethanol - water (8:2 v/V))
IR (Nujol) : 3300, 1640, 1590, 1545, 990, 860 cm 1
NMR (DMSO-d, §) + 1.4-2.4 (6H, m), 2.19 (6H, s), 2.6-3.2 (74, m), 6.11 (1H, 4, J=15Hz), 6.7-7.6 (10H, m), 7.95 (1H, m), 10.82 (1H, m)
MASS (m/e) : 443 (M%), 213 (base)
Elemental analysis : C,gH34N30,°4/3H,0 caled. : C 71.92, H 7.69, N 8.99 15 . Found : C 72.00, H 7.69, N 8.88 (7) 1-[2-{5- (4-Hydroxy-3,5-diisopropylphenyl)- (2E,4E)- 2,4-pentadienoylamino}ethyl]-4-(3-indolyl)piperidine mp : 110-120°C (recrystallized from ethanol - water (8:2 V/V))
IR (Nujol) : 3400, 3300, 1650, 1630, 1585, 995, 870 em 1
NMR (DMSO-d, §) : 1.28 (12H, 4, J=8Hz), 1.5-2.4 (6H, m), 2.7-3.6 (9H, m), 6.13 (1H, 4, J=15Hz), 6.8-7.6 (10H, m), 7.95 (1H, m), 8.4 (1H, m), 10.73 (1H, m)
MASS (m/e) : 499 (MT), 226, 213 (base)
Elemental analysis : C3pH, N30, "HHO calcd. : C 74.24, H 8.37, N 8.11
Found : C 73.84, H 8.42, N 7.97 (8) 1-[2-{5-(4-Hydroxy-3-methylphenyl)-(2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine a mp : 138-141°C (recrystallized from a mixture of - 35 ethanol - water (8:2 V/V))
IR (Nujol) : 3200, 1640, 1575, 1550, 1000 cm ©
Cod Lon Vly CL voter nt
NMR (DMSO-d, §) : 1.5-3.6 (13H, m), 2.20 (3H, s), 6.10 (1H, 4, J=15Hz), 6.7-7.7 (11H, m), 7.93 (1H, m), 9.65 (1H, m), 10.73 (1H, m)
MASS (m/e) : 429 (M'), 213 (base)
Elemental analysis : C,4H3N30,°5/4H,0 caled. : C 71.73, H 7.47, N 9.29
Found : C 71.78, H 7.73, N 9.28 (9) 1-[2-{5-(3-Chloro-4-hydroxyphenyl)~(2E,4E)-2,4~ pentadienoylamino}ethyl]-4-(3-indolyl)piperidine mp : 139-155°C (recrystallized from ethanol - water)
IR (Nujol) : 3420, 1650, 1590, 1000 —
NMR (DMSO-d, §) : 1.5-3.5 (13H, m), 6.12 (1H, 4,
J=15Hz), 6.7-7.7 (11H, m), 7.98 (lH, m), 10.7 (1H, m)
MASS (m/e) :. 449 (M'), 213 (base) : <¢ Elemental analysis : C,H, gCIN0,-1.5H,0 calcd. : C 65.47, H 6.55, N 8.81
Found : C 65.88, H 6.44, N 8.78 : (10) 1-{2-{5-(3,5-Dichloro-4-hydroxyphenyl)- (2E,4E)- 2,4-pentadienoylaminolethyl]-4-(3-indolyl)piperidine mp : 165-175°C (recrystallized from N,N-dimethyl- formamide)
NMR (DMSO-d, §) + 1.5-3.6 (13H, m), 5.3 (1H, m), 6.08 (lH, 4, J=15Hz), 6.6-7.6 (10H, m) , 8.09 (lH, m), 10.75 (lH, s)
MASS (m/e) : 485 (M+2), 483 (M'), 213 (base) (11) 1-[2-{5- (2-Hydroxy-3-methoxyphenyl) - (2E, 4E)-2,4- pentadienoylamino}ethyl}-4~(3-indolyl)piperidine mp : 184-186°C (recrystallized from ethanol)
IR (Nujol) : 3400, 3240, 1650, 1605, 1600, 1530, 1090, 1005 cm
NMR (DMSO-d, §) : 1.4-3.6 (13H, m), 3.78 (3H, s),
6.11 (lH, d, J=15Hz), 6.6-7.65 (11H, m), 7.90 (1H, t like), 8.95 (1H, br), 10.75 : (lH, s)
MASS (m/e) : 445 (M7), 226, 213 (base) i (12) 1-[2-{5- (3-Hydroxy-4-methoxyphenyl)- (2E,4E)~2,4- pentadienoylamino }ethyl}-4-(3-indolyl)piperidine mp : 135-140°C (recrystallized from ethanol)
IR (Nujol) : 3350, 1650, 1615, 1590 emt
NMR (DMSO-d., 8) : 1.4-3.5 (13H, m), 3.75 (3H, s}, 6.11 (1H, 4, J=15Hz), 6.6-7.7 (11H, m), 7.91 (1H, t like), 9.0 (1H, br), 10.7 (14, s)
MASS (m/e) : 445 (M'), 213 (base)
Example 8 : :
To a mixture of 1-[2-{5- (4-hydroxy-3-methoxyphenyl) - (2E,4E)-2,4-pentadienoylamino}ethyl]-4- (3-indolyl)- piperidine (0.89 gq), dry N-methylmorpholine (1.0 g) and dry N,N-dimethylformamide (10 ml) was added slowly acetyl chloride (0.26 g) at 5 to 10°C. After stirring for - 1 hour, the reaction mixture was poured into water (50 ml) and stirred for 1 hour. The resulting precipitate was collected, washed with water and then recrystallized : from a mixture of ethanol and water (7:3 V/V) to give 1- [2-15- (4-acetoxy-3-methoxyphenyl)— (2E, 4E)-2, 4-penta- dienoylamino}ethyl]-4-(3-indolyl)piperidine (0.22 g). mp : 101-105°C (recrystallized from ethanol - water (8:2, V/V))
IR (Nujol) : 3440, 3250, 1760, 1655, 1620, 1560, | 1505 cm
NMR (DMSO-d, §) : 1.5-2.4 (6H, m), 2.24 (3H, s), 2.6-3.5 (7H, m), 3.81 (3H, s), 6.20 (1H; 4, 'J=15Hz), 6.8-7.7 (11H, m), 8.04 (1H, m), 10.73 (1H, s) :
MASS (m/e) : 487 (M'), 213 (base)
Co Cte ee Cee
Elemental analysis : C,gH33N40, HO caled. : C 68.89, H 6.98, N 8.31
Found : C 68.91, H 6.95, N 8.32
Example 9 1- [2-{5~- (3-Methoxy-4-propionyloxyphenyl)- (2E, 4E) = 2, 4-pentadienoylamino }ethyl]-4-(3-indolyl) piperidine was obtained according to a similar manner to that of
Example 8. mp : 157-158°C (recrystallized from ethanol) : IR (Nujol) : 3430, 3250, 3060, 1750, 1655, 1620, 1560 cmt
NMR (DMSO-d, §) : 1.15 (3H, t, J=8Hz), 1.5-2.4 (6H, m), 2.62 (2H, gq, J=8Hz), 2.4-3.2 (5H, m) , 3.33 (2H, m), 3.82 (3H, s), 6.22 (1H, 4,
J=15Hz), 6.8-7.7 (11H, m), 8.05 (1H, m), : 10.75 (lH, s)
MASS (m/e) : 501 (M%), 213 (base) | oo
Elemental analysis : C3oH35N30,4 HO ‘calcd. : C 69.34, H 7.18, N 8.09
Found : C 69.14, H 7.09, N 8.06
Example 10 - To a mixture of 1-[2-{5-(4-hydroxy-3,5-dimethoxy- phenyl)-(2E,4E)-2,4-pentadienoylamino}ethyl]-4-(3- indolyl) piperidine (1 g) and pyridine (10 ml) was added slowly acetyl chloride (0.48 ml) at 5 to 10°C. After 1 hour, the reaction mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride and dried over magnesium sulfate. The solvent was distilled off and the residue was subjected to column chromatography on silica gel and eluted with a mixture of chloroform and methanol (L0:1 v/v). The fractions containing the object compound were combined and concentrated under reduced pressure. The residue was treated with a mixture of fumaric acid (83 mg) and methanol (8 ml) and concentrated under reduced pressure . to give white crystals. The crystals were recrystallized from ethanol to give 1-[2-{5-(4-acetoxy-3,5-dimethoxy- phenyl) - (2E,4E)-2, 4-pentadienoylamino}ethyl]-4-(3-. indolyl)piperidine 1/2fumarate (0.25 g). mp : 202-209°C
IR (Nujol) : 3400, 1750, 1680, 1615, 1595, 1565 cm ©
NMR (DMSO-d, §) : 1.6-2.15 (5H, m), 2.32 (3H, s), 2.2-3.6 (8H, m), 4.82 (6H, s), 6.22 (lH, 4,
J=14Hz), 6.64 (lH, s), 6.7-7.7 (10H, m), 8.29 (1H, m), 10.75 (1H, s)
MASS (m/e) : 517 (M'), 213 (base) . 15 Elemental analysis : CoH 45M 0" 1/2Fumarate * 3/2H,0
Calcd. : C 63.77, H 6.68, N 6.97
Found : C 63.57, H 6.44, N 6.95
Example 11 1-[2-(5~-(3,5-Dimethoxy-4-propionyloxyphenyl)- (2E, 4E)- ; 2,4-pentadienoylaminolethyl]-4- (3-indolyl)piperidine 1/2fumarate was obtained according to a similar manner to that of Example 10. mp : 188-192°C (recrystallized from ethanol)
IR (Nujol) : 3400, 1745, 1680, 1615; 1595, 1565 cm!
NMR (DMSO-d, 8) : 1.13 (3H, t, J=7Hz), 1.6-2.2 (3H, m), 2.2-3.7 (12H, m), 3.81 (6H, s), 6.21 (lH, d, J=15Hz), 6.62 (lH, s), 6.87.6 (10H, m), 8.3 (1H, m), 10.78 (1H, s)
MASS (m/e) : 531 (M'), 213 (base)
Elemental analysis : C, H,,N,0 -1/2Fumarate - 3/2H,0
Calcd. : C 64.27, H 6.86, N 6.81
Found : C 64.17, H 6.78, N 6.78 oo
Example 12
To a mixture of 1-[2-{5-(4-hydroxy-3,5-dimethoxy- phenyl) - (2E,4E) -2, 4-pentadienoylamino}ethyl]-4- (3-indolyl)- piperidine (1.19 g), triethylamine (1.74 ml) and dry
N,N-dimethylformamide (12 ml) was added slowly a mixture of ethyl chloroformate (0.33 g) and methylene chloride (0.5 ml) at 0 to 5°C. Similar work up gave 1-(2-{5-(4- ethoxycarbonyloxy-3,5-dimethoxyphenyl)- (2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine (0.74 gq). mp : 90-98°C (recrystallized from ethanol - water (8:2 v/V))
IR (Nujol) : 3360, 3300, 1750, 1640, 1590, 1130, 1000, 735 cm *
NMR (DMSO-d, §) : 1.28 (3H, t, J=8Hz), 1.5-3.6 (134, m), 3.81 (6H, s), 4.23 (2H, gq, J=8Hz), 6.21 (1H, 4, J=15Hz), 6.8-7.7 (10H, m), 8.05 (1H, m), 10.71 (1H, s) -
MASS (m/e) : 547 (MT), 228, 213 (base)
Elemental analysis : C4 H34N306"2.5H,0
Calcd. : C 62.82, H 7.14, N 7.09
Found :: C 62.74, H 6.93, N 7.05
Example 13
The following compounds were obtained according to a similar manner to that of Example 12. (1) 1- (4-{5- (4-Ethoxycarbonyloxy-3,5-dimethoxyphenyl)- (2E,4E)-2, 4-pentadienoylamino}butyl}-4-(3-indolyl)- piperidine mp : 90-98°C (recrystallized from ethanol - water (8:2 V/V))
IR (Nujol) : 3380, 3250, 1750, 1655, 1620, 1595, 1555, 1130, 1050, 1000, 735 cm ©
NMR (DMSO-d, §) : 1.27 (3H, t, J=8Hz), 1.4-3.7 (L7H, m), 3.72 (6H, s), 4.23 (2H, gq, J=8Hz),
6.20 (lH, 4, J=15Hz), 6.8-7.75 (10H, m) , 8.10 (1H, m), 10.76 (lH, s)
MASS (m/e) : 575 (M'), 531, 503, 285, 233, 213 (base)
Elemental analysis : C,4H, N40¢ -3/2ethanol calcd. : C 67.01, H 7.81, N 6.52
Found : C 66.39, H 7.74, N 6.52 (2) 1-[4-{5-(3,5-Dimethoxy-4-propionyloxyphenyl)- (2E,4E)- 2, 4-pentadienoylamino}butyl]-4-(3-indolyl)piperidine hydrochloride mp : 215-220°C (recrystallized from acetonitrile)
IR (Nujol) : 3250, 2650, 2500, 1760, 1650, 1595, 1130, 1010, 850, 750 em
NMR (CDC1 4, §) + 1.29 (3H, t, J=8Hz), 2.65 (2H, gq,
J=8Hz), 1.5-3.7 (17H, m), 3.80 (6H, s), 6.35 (1H, 4, J=15Hz), 6.6-7.7 (10H, m), 7.9 (lH, m), 9.05 (1H, m), 11.3 (1H, m)
MASS (m/e) : 559 (M'), 503, 233, 213 (base) - (3) 1- [2- [5-{3,4-bis (Ethoxycarbonyloxy)phenyl}- (2E, 4E) - 2, 4-pentadienoylamino]ethyl]-4- (3-indolyl) piperidine mp : 135-137°C (recrystallized from a mixture of water and ethanol) Lo
IR (Nujol) : 3500, 3350, 1775, 1650, 1620, 1000 ont
NMR (DMSO-d, 8) : 1.30 (6H, t, J=8Hz), 1.3-3.5 (13H, m), 4.30 (4H, gq, J=8Hz), 6.25 (1H, 4, J=15Hz), 6.6-7.7 (11H, m), 8.08 (1H, m), 10.73 (1H, s)
MASS (m/e) : 529 (M'-46), 457, 285 (base), 213
Example 14
To a mixture of 1-[2-{5-(4-hydroxy-3,5-dimethoxy- phenyl) - (2E, 4E) -2, 4-pentadienoylamino}ethyl]-4- (3-indolyl)- piperidine (2.0 g), triethylamine (2.9 ml) and dry N,N- dimethylformamide (20 ml) was added slowly a solution of acetylchloride (0.5 g) in methylene chloride (1.0 ml)
Cs - . " at 0 to 5°C. After 1 hour, the reaction mixture was poured into water (200 ml) and stirred for 1 hour. The resulting precipitate was collected, washed with water and air-dried at ambient temperature. The precipitate was subjected to column chromatography on silica gel (60 g) and eluted with a mixture of chloroform and methanol (20:1 V/V). The fractions containing the object compound were combined and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate to give pale yellow crystals of 1-[2-{5-(4~ acetoxy-3, 5-dimethoxyphenyl)- (2E,4E)~2, 4-pentadienoylamino}- ethyl]-4- (3-indolyl)piperidine (1.35 g). mp : 169-172°C
IR (Nujol) : 3380, 3320, 1755, 1650, 1620, 1595, 990, 745 cm ©
NMR (CDCl,, 8) : 1.5-3.6 (13H, m), 2.32 (3H, 8), . ~.° 3.82 (6H, s), 6.0 (1H, d, J=15Hz), 6.34 (1H, m), 6.7-7.7 (10H, m), 8.32 (1H, m)
MASS (m/e) : 517 (M'), 213 (base)
Elemental analysis : C30H35N305 . calcd. : C 69.61, H 6.82, N 8.12
Found : C 69.35, H 6.82, N 8.02 25 . To a stirred mixture of 5-[3,5-dimethoxy-4- { (2-methoxyethoxy)methoxy}phenyl]-(2E,4E)-2,4-pentadiencic acid (1.35 g) and triethylamine (1.17 ml) in dry N,N- -dimethylformamide (8 ml) was added slowly diphenyl phosphinic chloride (0.97 g) at -10 to -15°C under an inert atmosphere. After being stirred for 1 hour, a solution of 1-(2-aminoethyl)-4-(3-indolyl)piperidine (0.97 g) in dry
N,N-dimethylformamide (8 ml) was added slowly to the reaction mixture at the same temperature. After being stirred for 40 minutes at the same temperature, the reaction mixture was poured into ice-water (160 ml) and extracted with ethyl acetate. The extract was washed with a saturated sodium chloride solution and dried over magnesium sulfate.
The solvent was evaporated to give syrup of 1-[2-[5-(3,5- dimethoxy-4-{ (2-methoxyethoxy)methoxy}phenyl]-(2E,4E)-2,4- pentadienoylamino]ethyl]-4-(3-indolyl)piperidine (1.97 g).
IR(Nujol): 3300, 1650, 1610, 1580, 1125, 990, 960, 845, 745 cm
Example 16
To a hot solution of citric acid hydrate (2.65 g) in a mixture of water and ethanol (4:6, V/V, 50 ml) was added ' 1-12-{5-(4-hydroxy-3,5-dimethoxyphenyl)~-(2E,4E)-2,4- pentadienoylamino}ethyll-4-(3-indolyl)piperidine {6.0 g), and then a mixture of water and ethanol (4:6, V/V, 50 ml) was added thereto. The mixture was stirred for 6 hours at ambient temperature, and the resulting precipitate was collected by filtration. The residue was washed with a mixture of water and ethanol, and dried to give Co 1-[2-{5-(4-hydroxy-3,5-dimethoxyphenyl)-(2E,4E)~2, 4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine citrate (7.2 9g). mp : 140-142°C
IR (Nujol) : 3600, 3370, 3300, 1745, 1645 cm!
NMR (DMSO-d, 8) : 1.78-2.10 (4H, m), 2.8-3.2 (5H, m), 3.33-3.62 (4H, m), 3.80 (6H, s), 6.11 (1H, 4, J=14.8Hz), 6.8-7.25 (8H, m), 7.36 (1H, d,
J=7.9Hz), 7.61 (1H, 4, J=7.5Hz), 8.35 (1H, br), 10.86 (1H, br s)
Example 17
A mixture of 1-[2-{5-(4-hydroxy-3,5-dimethoxyphenyl)- (2E,4E)-2,4-pentadienoylamino}ethyl]-4-(3-indolyl)- : piperidine (7.0 g), fumaric acid (1.708 g) and methanol
(200 ml) was refluxed. After the solid was completely dissolved, the mixture was filtered and the filtrate was allowed to stand at ambient temperature. The resulting precipitate was collected by filtration, washed with methanol (10 ml) and dried to give 1-[2-{5-(4-hydroxy- 3,5-dimethoxyphenyl)-(2E,4E)-2, 4-pentadienoylaminojethyl]}- 4-(3-indolyl)piperidine fumarate (7.58 g). mp : 138-140°C
IR (Nujol) : 3400-3150, 1700, 1645 cmt
NMR (DMSO-d, 8) : 1.75-2.1 (4H, m), 2.5-3.0 (5H, m), 3.15-3.5 (4H, m), 3.80 (6H, s), 6.09 (1H, 4, J=14.8Hz), 6.60 (2H, s), 6.77-7.15 (8H, m), 7.33 (1H, 4, J=7.8Hz), 7.59 (1H, 4,
J=7.4Hz), 8.38 (1H, t like), 10.82 (1H, br s)
Example 18
The following compounds were obtained according to a similar manner to that of Example 17. (1) 1-[2-{5-(4-Hydroxy-3,5-dimethoxyphenyl)-(2E,4E)-2,4~ pentadienoylamino}ethyl]-4-(3-indolyl)piperidine (-)-tartrate (510 mg) was obtained from 1-[2-{5-(4- hydroxy-3,5-dimethoxyphenyl) -(2E, 4E) -2, 4-pentadienoyl- amino}ethyll-4-(3-indolyl)piperidine (0.5 g) and (-)-tartaric acid (158 mg). mp : 144-147°C (dec.)
IR (Nujol) : 3450-3150, 1710, 1645, 1600 cm *
NMR (DMSO-d, §) : 1.75-2.10 (4H, m), 2.5-3.0 (5H, m), 3.2-3.5 (4H, m), 3.80 (6H, s), 4.14 (2H, s), 6.10 (1H, d, J=14.8Hz), 6.8-7.26 (8H, m), 7.34 (1H, 4, J=7.8Hz), 7.59 (1H, 4, J=7.4Hz), 8.34 (1H, t like), 10.82 (1H, br s) (2) 1-[2-{5-(4-Hydroxy-3,5-dimethoxyphenyl)-(2E,4E)-2,4~ pentadienoylamino}ethyl]-4-(3-indolyl)piperidine succinate (0.25 g) was obtained from 1-[2-{5-(4-hydroxy-3,5- dimethoxyphenyl)-(2E,4E)-2,4-pentadienoylamino}ethyl]-4- (3-indolyl)piperidine (0.5 g) and succinic acid (124 mg). mp : 95-105°C (dec.)
IR (Nujol) : 3400-3100, 1720, 1650, 1590 emt
NMR (DMSO-d, §) + 1.61-2.12 (4H, m), 2.17-2.22 (24, m), 2.40 (4H, s), 2.5-2.6 (2H, m), 2.7-2.9 (1H, m), 3.0-3.17 (2H, m), 3.23-3.42 (2H, m), 3.80 (6H, s), 6.10 (1H, 4, J=14.8Hz), 6.78-7.25 (8H, m), 7.33 (1H, 4, J=7.8Hz), 7.55 (1H, 4, J=7.4Hz), 8.07 (1H, t like), 10.78 (1H, br s)
Example 19
To a hot solution of (+)-tartaric acid (2.21 g) in a mixture of ethanol and water (9:1, V/V, 200 ml) was added 1-[2-{5-(4-hydroxy-3,5-dimethoxyphenyl) -(2E,4E)-2, 4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine (7.0 g) under bubbling nitrogen gas. After a mixture of ethanol and water (9:1, V/V, 80 ml) was added thereto, the mixture was refluxed for 5 minutes and then stirred for 3 hours at ambient temperature. The resulting precipitate was collected by filtration, washed with a mixture of ethanol and water (9:1, V/V, 20 ml) and dried to give 1-[2-{5-(4-~ hydroxy-3,5-dimethoxyphenyl)-(2E,4E)-2,4-pentadienoyl- amino}ethyll-4-(3-indolyl)piperidine (+)-tartrate. (8.18 g). mp : 142-146°C
IR (Nujol) : 3450-3150, 1710, 1645, 1600 cmt
NMR (DMSO-dg, 8) : 1.73-2.15 (4H, m), 2.5-3.0 (5H, m), 3.17-3.5 (4H, m), 3.80 (6H, s), 4.13 (2H, s), 6.10 (1H, 4, J=14.8Hz), 6.8-7.26 (84, m), 7.34 (1H, 4, J=7.8Hz), 7.58 (1H, 4,
J=7.4Hz), 8.30 (1H, t like), 10.82 (1H, br s)
on . ’ - 57 -
Example 20 1-[2-(5-(A-hydroxy-3,5-dimethoxyphenyl)-(2E, 4E)-2,4~ pentadienoylamino)ethyl]-4-(3-indolyl)piperidine (4.5 g) was dissolved in a mixture of methanol (90 ml), 1N hydrochloric acid (18.9 ml) and water (19.8 ml), and water (51.3 ml) was dropwise added thereto at ambient temperature. The resulting precipitate was collected by filtration, washed with ethanol (9 ml) and dried to give 1-[2-{5-(4-hydroxy-3,5-dimethoxyphenyl)-(2E,4E)-2,4- pentadienoylamino}ethyl]-4-(3-indolyl)piperidine hydrochloride (4.30 g). : mp : 155°C
IR (Nujol) : 3350, 2650, 1640, 1620 emt
NMR (DMSO-d, §): 2.0-2.3 (4H, m), 3.0-3.3 (5H, m), 3.5-3.75 (4H, m), 3.80 (6H, s), 6.13 (1H, 4,
J=14.8Hz), 6.8-7.4 (9H, m), 7.69 (1H, 4,
J=7.7Hz), 8.67 (1H, m), 8.72 (1H, s), 10.60 (1H, : br s), 10.93 (1H, s)
Claims (2)
1. © An acid addition salt of 1-[2-{5-(4-hydroxy- 3,5-dimethoxyphenyl)-(2E,4E)-2,4- : pentadienoylaminn}ethyl]-4-(3-indonlyl)-piperidine,
2. A compound of claim 1, which is 1-[2-{5-(4- hydroxy-3,5-dimethoxyphenyl)-(2E,4E)-2,4- prentadienoylamino}-ethyl}-4~(3-indolyl)piperidine citrate, Inventors: MASAAKI MATSUO TAKASHI MANABRE SHINJI SHIGENAGA HIROSHI MATSUDA : i + Co mr TITS A . BAD ORIGINAL © L
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/414,022 US5017703A (en) | 1988-01-14 | 1989-09-28 | Indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26557A true PH26557A (en) | 1992-08-19 |
Family
ID=23639640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH40436A PH26557A (en) | 1989-09-28 | 1990-04-27 | Indolylpiperidine compounds |
Country Status (1)
Country | Link |
---|---|
PH (1) | PH26557A (en) |
-
1990
- 1990-04-27 PH PH40436A patent/PH26557A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5017703A (en) | Indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | |
AU667107B2 (en) | Thiazolylvinylphenyl derivatives | |
US6087357A (en) | Piperazine derivatives as tachykinin antagonists | |
RU2125051C1 (en) | Derivatives of diphenyl, derivative of phenylpiperazine, method of patients treatment | |
JP2000502330A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their use as medicaments, and methods and intermediates useful for their production | |
US4839353A (en) | Anti-ulcer substituted pyridine derivatives | |
DE19753522A1 (en) | Substituted indoles, their preparation and their use as pharmaceuticals | |
US5055477A (en) | Pyrazolyl acrylic acid derivatives, useful as systemic fungicides for plant and material protection | |
EP0757670B1 (en) | Benzamide derivatives as vasopressin antagonists | |
WO1998057954A1 (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | |
EP1051415B1 (en) | Benzamide derivatives as vasopressin antagonists | |
EP0505954A1 (en) | N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity | |
JPH10287634A (en) | Benzene derivatives | |
CA2146261A1 (en) | Sulfonamide derivatives of benzenefused, hydroxy substituted cycloalkyl and heterocyclic ring compounds | |
JPH08119936A (en) | Heterocyclic derivative | |
PH26557A (en) | Indolylpiperidine compounds | |
PH27110A (en) | New indolypiperidine compounds processes for the preparation thereof and pharmaceutical composition comprising the same | |
HUT51615A (en) | Process for producing new 3,4,5-substituted 4h-1,2,4-triazoles and pharmaceutical preparations containing them | |
KR20020025255A (en) | Amide compounds | |
HU199813B (en) | Process for producing new benzothiazinone derivatives and pharmaceutical compositions comprising such active ingredient | |
CA2199889A1 (en) | Use of naphthalene derivatives in treating lung carcinoma | |
JPH04244073A (en) | Thiazole compound | |
HU206703B (en) | Process for producing indolyl-piperidine derivatives and pharmaceutical compositions containing them | |
AU743723B2 (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | |
JPS596306B2 (en) | New method for producing N-substituted triazolone derivatives |